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CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
1. Pathogenesis of the metastatic process 
From the clinical point of view the expression "neoplastic malignancy" means the 
ability of tumor cells to disseminate and form metastases Metastasis is defined as the 
transfer of disease from one organ to another not directly connected with it (1-4) This 
ability to invade and metastasize is unique to malignant neoplasms, and is responsible 
formosi therapeutic failures in clinical oncology The majority of tumors have already 
metastasized at the time of diagnosis often it is impossible to remove metastases 
because of their anatomical location and often metastases do not respond or become 
resistant to conventional therapies 
Death rates among cancer patients thus partly depend on the malignant properties 
of the cells that compose the primary tumor Therefore experimental research to clarify 
the metastatic process is important not only for the biology of cancer, but also for new 
therapeutic approaches 
The metastatic cascade 
In the last decade it has become clear that cancer arises through a change in the 
genes that regulate the division and the ripening of cells These changed genes are 
called oncogenes Oncogenes may playa role in tumor progression either by effects on 
growth potential or by affecting other properties important for metastatic capacity 
Malignant progression is driven by the expression of oncogenes and loss of expression 
of tumor suppressor genes, which can also be called growth suppressor genes When 
these genes are lost, cell growth becomes uncontrolled 
The molecular mechanisms responsible for the formation of metastasis are very 
complex, and still not completely elucidated Metastasis is a multistep process that 
involves the release of cells from the primary tumor, local invasion and penetration 
in the capillary bed, dissemination to distant sites through the lymphatic system 
(preferentially used by carcinomas) or the hematogenous route (preferentially used by 
tumors of mesenchymal origin), arrest in the microcirculation of secondary organs, 
extravasation and growth in the parenchyma of those organs (5) (Fig 1) Only few cells 
are able to complete this process and interruption of the metastatic cascade at any of 
these steps can prevent metastasis formation For example, the mere presence of 
tumor cells in the circulation does not mean they will form metastasis, since most of 
them will be eliminated rapidly by the host's immune and non-immune responses 
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In the Seventies and Eighties it was found that only a small number of cells 
(estimated at <0.01%) from the primary tumor are able to form metastases (3,6). The 
tumor cell population within the primary tumor is heterogeneous in many aspects. 
The pathogenesis of a metastasis 
Transport 
Interaction with host 
platelets, lymphocytes and 
other blood elements 
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Figure 1. Schematic illustration of the major steps m the pathogenesis of metastasis. Initial neoplastic 
transformation of susceptible cells gives rise to a small population of tumor cells Vascularisation of this 
early neoplastic lesion allows further proliferation of tumor cells and enlargement of the primary tumor 
Malignant cells xvithm the primary tumor next begin to invade the surrounding host tissue(s). Entry of 
invading tumor cells into lymphatics or blood vessels enables them to travel to distant sites in the body 
where they lodge and arrest m the capillary beds of secondary organs For illustrative purposes this figure 
depicts the arrest of malignant cells m the lung capillary bed The cells then move out from capillaries into 
the surrounding lung paienchyma where, m a suitable envuonmenl, they can proliferate and form 
metastases 
Reproduced from Po^te С and Fidler Ij Nature 2S3 139-146. Ί9&0 
The morphological, genetic, biochemical and antigenic heterogeneity gives the cells 
different abilities to invade and form metastases (3,6-8) Not only is the primary tumor 
heterogeneous, but also the cell population of their metastases. This makes therapy 
problematic, because some lumor cells will be resistant to conventional therapies. 
A critical phase in the metastatic process is the interaction of circulating tumor cells 
Primary malignant 
neoplasm 
vascularisation 
Invasion 
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with the vessel wall (9-11). It has been shown that cells of certain tumor types 
preferentially metastasize in specific sites (12,13). Various explanations have been 
proposed for the site-selectivity of blood-borne metastases, including tumor cell surface 
characteristics (14), response to organ-derived chemotactic factors (15), adhesion to 
organ components (5,16-20) and response to specific host tissue growth factors (18). 
With the recent identification and characterization of specific cell surface molecules 
that mediate cell-cell and cell-substrate adhesion, the roles that these molecules' roles 
in the process of metastasis are being investigated. These molecules belong to different 
families: selectins, immunoglobilin superfamily, integrins, Cadherins (21,22), and other 
adhesion molecules have been described. 
It has been proposed that after tumor cell interaction with the endothelium (9,16,23-
25), the endothelium retracts, and tumor cells adhere firmly to the subendothelial 
extracellular matrix (11,26,27). The production of proteolytic enzymes, including matrix 
metalloproteinases (28,29), enables tumor cells to degrade the extracellular matrix and 
migrate in the perivascular interstitial stroma (11). After extravasation and invasion, 
the cells must proliferate and induce angiogenesis to form a metastasis (10,30). 
The adhesion of tumor cells to vascular endothelium and the degradation of 
extracellular matrix are therefore vital in metastasis formation. The understanding of 
these adhesion and degradation mechanisms should lead to new strategies to block 
these events, hence also the formation of metastases. 
2. Role of cytokines in tumor-endothelial cell interaction 
Cell-cell and cell-matrix adhesion plays an important role in inflammatory 
responses, embryogenesis, morphogenesis, hemostasis and maintenance of tissue 
integrity. Quantitatively and/or qualitatively abnormal adhesion processes can lead to 
a wide variety of pathological conditions such as neurological disorders, chronic 
inflammation and metastasis formation (11,20,31-35). 
Adhesion on, and extravasation through endothelium is a physiological process 
used by circulating white blood cells to eliminate, for example, foreign antigens outside 
of the blood vessel. Adhesion of these cells to endothelium (36,37) is induced and/or 
modified by inflammatory mediators such as cytokines. These proteins can be 
produced and secreted by many different cell types and regulate cell behavior in a 
paracrine or autocrine manner. Cytokines coordinate a number of interactions between 
cell types in multicellular organisms and play a major role in orchestrating the 
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immune response Interleukin-1 (IL-1) and tumor necrosis factor (TNF), two 
important cytokines and mediators of the acute inflammatory response, induce several 
functional alterations in endothelial cells (EC). The activation of these cells by IL-1 and 
TNF increases their adhesiveness for polymorphonuclear leukocytes, eosinophils, and 
lymphocytes (38-46) This is mainly caused by the synthesis and expression of the 
adhesive receptors on EC, E-selectin previously known as ELAM-1, or by enhanced 
expression of intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion 
molecule-1 (VCAM-1) (39,47-49) Similarly, activation of cultured EC by IL-1 and TNF 
increases the adhesion of tumor cells of different histological type and origin (50-52) 
This has led to the concept that tumor cell extravasation from the bloodstream during 
metastasis formation resembles in many aspects the entry of normal circulating cells 
into inflammatory tissue In chapter 2 of this thesis we describe how the interleukin-1 
receptor antagonist (IL-lra) can block the increased adhesion of TC on EC activated by 
IL-1 (53) 
Cytokines and other stimuli, such as endotoxin and thrombin, have numerous 
other effects that might be relevant to inflammation These include release of platelet-
activating factor (PAF), prostaglandins, and platelet-derived growth factor (PDGF) (for 
review (54)) The endothelium itself is capable of synthesis and secretion of cytokines 
For example, IL-1 production can be induced by endotoxin, thrombin, or TNF (55-58), 
and may serve to amplify the proinflammatory effects of the original stimulus 
Tumor cells too can release cytokines, and induce an inflammatory response that in 
turn is responsible for the augmented adhesion to EC mediated by the increased 
expression of adhesion molecules We deal with this topic in Chapter 4, transfecting a 
human melanoma with a gene that encodes for IL-la 
E-selechn 
E-selectin is a member of the selectin family of adhesion molecules that shares a 
common structure consisting of an N-terminal lectin-like portion which recognizes a 
carbohydrate ligand (ι e Sialyl-Lewis x/Sialyl-Lewis a)(59) E-selectin is expressed only 
on activated EC and is inducible by inflammatory/immune mediators such as IL-1, 
TNF, and LPS in 3-4 hours (Tab 1) E-selectin was first described as mediating the 
adhesion of neutrophils to activated endothelium (49), and in Chapter 7 we show that 
E selectm also plays a role in colon carcinoma-ЕС adhesion (60) 
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V CAM-I 
VCAM-1 is a member of the immunoglobulin superfamily, and is minimally 
expressed on resting EC IL-1, TNF, and LPS (52) cause synthesis and expression of 
VCAM-1, that reach a plateau at 6-24 hours (Tab 1) Receptors for VCAM-1 on EC 
surface are the very late antigen-4 (VLA-4), an a4ßl ìntegrin molecule (61), and the 
more recently identified a4ß7 integrin (62) VLA-4 is expressed on monocytes, 
lymphocytes, and several tumor cells (63,64) In Chapter 3 of this thesis we show that 
VLA-4 expression on melanoma cells is implicated in metastasis formation, by 
adhesion on EC which express the counter-receptor VCAM-1 (65) 
Table 1. Charatensttcs of three different endothelial cell adhesion molecules 
Endothelial adhesion 
molecule Family Struct lie Expression (peak) Llgand 
EGFJihe 
Domain 
E-seteclin Selectn Ч°™Ш$ШШШШ-^^~соон Inducble (3 4h) Carbohydrate 
VCAM-1 Immunogtobuin ин
г
 . „ J T f f i f J f ?°Г *Τϊ czl 5 ^ Inducible (6 24h) Integnn 
superlamiy {£3k£2b£3kS3*&*&£9
 (,IOKD) COOH 
ICAM-1 Immunoglobulin щ Constitutive (12 24h) Integnn 
superfamily d KcjXçp^^c^) «== >соон (Indudble) 
(96 hü) 
ICAM-1 
ICAM-1 is also a member of the immunoglobulin super-family It is expressed 
constitutively on many cell types including EC and leukocytes, and is involved in the 
extravasation of neutrophils, monocytes and lymphocytes ICAM-1 expression is 
strongly induced after stimulation of vascular EC with IL-1, TNF, and interferon-γ 
(IFN-Y)(66) The plateau of expression is reached at 12-24 hours (Tab 1) The hgands are 
the integrins Mac-1 and lymphocyte-functioning antigen-1 (LFA-1) on lymphocytes 
and neutrophils (67-69) 
Although the kinetics of ICAM-1 and VCAM-1 expression are similar, there are 
some important differences in their regulation First, ICAM-1 expression is higher on 
unstimulated EC and second, ICAM-1 expression appears somewhat more sustained 
The difference in the kinetics has been exploited to study their different adhesion 
mechanisms 
Increased expression of ICAM-1 is correlated with melanoma tumor progression 
and increased risk of metastasis (70) Soluble forms of ICAM-1 can be released by 
melanoma cells In Chapter 5 we show that serum from nude mice bearing 
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subcutaneous human melanoma tumors contains elevated levels of soluble human 
ICAM-1 These ICAM-1 levels showed positive correlation with tumor weight (71) 
Soluble ICAM-1 release by tumor cells may provide additional escape mechanisms 
Shedding of ICAM-1 by melanoma cells in response to cytokines might leave 
insufficient cell surface ICAM-1 for recognition by cytotoxic lymphocytes It is also 
possible that high local concentrations of soluble ICAM-1 block fJ2 integrin sites on 
leukocytes and therefore block immune recognition Finally, detection of soluble 
ICAM-1 in serum offers a potential prognostic marker for malignant melanoma The 
diagnostic potential may, however, be limited, since serum ICAM-1 can be elevated in 
a wide range of inflammatory diseases (72) 
E-selectin and VCAM-1 can also be shed in soluble form, and levels in blood are 
higher in different kinds of cancer than in healthy donors (72-75) The biological 
significance of circulating adhesins in tumor progression is not yet clear 
Two of the above described molecules, E-selectin and VCAM-1, appear to play a 
pivotal role in the tumor cell-EC interaction, though tumor types of different 
histological origin preferentially use different adhesion mechanisms For example, 
selectin-carbohydrate interactions preferentially support the adhesion of colon 
carcinomas (59,63,76-78), while VCAM-1-integrin interactions mediate the adhesion of 
melanomas and osteosarcomas to activated EC (63,64,78) See also Chapter 7 of this 
thesis 
3. Matrix mctalloproteinases (MMPs) and their tnltibttors 
After tumor cells attach to EC, it retracts, and tumor cells adhere firmly to the 
subendothelial extracellular matrix (ECM) This interaction is mediated by cell surface 
receptors, which recognize glycoproteins of the ECM such as laminin, type IV collagen, 
fibronectin and proteogycans To penetrate the ECM and migrate, tumor cells secrete 
degradative enzymes or induce the host to elaborate proteinases to degrade the matrix 
Matrix lysis takes place close to the tumor cell surface (79), where the amount of active 
enzyme produced by the tumor cell outbalances the natural proteinase inhibitors 
present in serum, in the matrix, or secreted by stromal cells 
Previous studies have shown that the invasive capacity of tumor cells is related to 
the presence of MMPs that are responsible for the breakdown and remodeling of 
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basement membrane and interstitial matrix (28,29) MMPs are a family of Zn 2 + 
dependent endopeptidases with a broad spectrum of proteolytic activity for several 
components of the ECM (28) The family has at least eleven members that range from 
M
r
 28,000 to 92,000 These are grouped in three broad categories based on substrate 
preference interstitial collagenase, type A and В gelatinases (M
r
 72,000 progelatinase, 
and M
r
 92,000 progelatinase) and stromelysin (rat transin) Interstitial collagenase 
(MMP-1) degrades collagen types I, II, III, VII and X, M
r
 72,000 progelatinase (MMP-2) 
and M
r
 92,000 progelatinase (MMP-9) degrade collagen types IV, V, VII and X 
Stromelysin (MMP-3) degrades fibronectin, laminin, and proteoglycans Recently a 
membane type matrix metalloproteinase (MT-MMP (MMP-14)) has been found that 
has a potential transmembrane domain and is expressed on the surface of invasive 
tumor cells (80) (See Table 2 for a complete list of MMPs) 
Table 2. Nomenclature and natural substrates of the matrix metalloproteinase family 
Enzyme 
Interstitial Collagenase 
Neutrophil Collagenase 
Collagenase 3 
Stromelysin-1 
Stromelysm-2 
Matrilysin 
Stromelysin-3 
Gelatinase-A 
Gelatmase-B 
Metalloelastase 
MT-MMP 
MMP No. 
MMP-1 
MMP-8 
MMP-13 
MMP-3 
MMP-10 
MMP-7 
MMP-11 
MMP-2 
MMP-9 
MMP-12 
MMP-14 
Matrix substrate(s) 
Fibrillar Collagene 
Fibrillar Collagens 
Fibrillar CoUagens 
Laminin, Fibronectin, non Fibrillar Collagens 
Lamirun, Fibronectin, поп-Fibrillar Collagens 
Laminin, Fibronectin, non-Fibrillar Collagens 
Serpm 
Type IV & V Collagens, Fibronectin 
Type Г & V Collagens 
Elastin 
proGelatinase-A 
This tabic presents recommended names and No for MMPs, together with their substrates 
Modified from Peter D Brown Pharireceutical News 2 29 32 1995 
All family members are secreted in a latent form and require removal of an 80-
amino acid ammo-terminal domain (± 10,000 daltons) to attain activity (81) Latency is 
due to a conserved cysteine that binds to zinc at the active site I atency is overcome b\ 
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physical (chaotropic agents), chemical (mercurials), and enzymatic (trypsin, plasmin) 
treatments that separate the cysteine residue from zinc (29) 
The synthesis, secretion, and activation of these zymogens together with the 
synthesis and secretion of their inhibitors (tumor inhibitor of metalloproteinase 
TIMP-1 (82,83) and TIMP-2 (84-86)) are key regulatory steps in remodeling of the 
extracellular matrix in both normal and pathological processes such as wound healing, 
angiogenesis, rheumatoid arthritis, and tumor invasion (49,87) 
Both native and synthetic inhibitors have been considered to develop MMP 
inhibitory therapies The native inhibitors, TIMP-1 and TIMP-2, are potent broad 
spectrum inhibitors (inhibiting collagenases, stromelysins and gelatinases) and have 
been in development as therapeutic agents since their identification and sequencing in 
1985 (TIMP-1 (53)) and 1989 (TIMP-2 (84)) However their therapeutic use is likely to be 
limited by their size, 28kD and 21kD respectively, which may limit tissue penetration 
Therefore pharmaceutical companies are trying to develop low-molecular-weight 
synthetic compounds to inhibit broad-spectrum MMPs One of the topics of this thesis 
is inhibition of the metastatic spread and growth of a murine melanoma by a synthetic 
MMP inhibitor called Batimastat (79,88) Batimastat is a substituted peptide derivative, 
analogous to the cleavage site in the collagen molecule with a metal-binding group in 
the position of the peptide bond 
4 Outline of the study 
The purpose of this thesis is to elucidate some aspects of the metastasic cascade We 
focussed on the roles of cytokines and adhesion molecules in the interactions of 
human melanoma cells on EC in vitro and in vivo In Chapter 2 we show that IL-lra 
block induction of different adhesion molecules by IL-1 on EC This means blocking 
the expression of adhesion molecules on EC, the augmented tumor cell adhesion on 
EC, and augmented metastasis formation Chapter 3 describes how VLA-4 is involved 
in IL-1-augmented experimental metastasis produced by melanoma The VLA 
4/VCAM-l interaction plays a role in melanoma-ЕС adhesion We found that pre­
treatment of human melanoma cells with a MAb against VLA-4 reduced their 
adhesion on VCAM-1 and reduced metastasis in IL-1 treated nude mice 
In Chapter 4 we demonstrate that IL-la produced constitutively by melanoma cells 
after IL-la gene transfer is functionally active, inducing adhesion molecules on FC that 
increase their adhesiveness for tumor cells and increase tumor cell retention in the 
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lungs of nude mice Chapter 5 reports that human melanoma cells release soluble 
ICAM-1 m vitro and in vivo In mice bearing human melanoma we show the 
association between ICAM-1 release and tumor burden We suggest that ICAM-1 
contributes to the malignancy of the tumor by escaping from host defense 
mechanisms Furthermore in Chapter 6 we tested a metalloproteinase inhibitor, 
batimastat, for preventing metastasis formation in mice bearing murine melanoma In 
Chapter 7 we review the role of inflammatory cytokines and adhesion molecules in 
metastasis formation This chapter can be considered a general discussion. 
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Interleukin-1 Receptor Antagonist inhibits the augmentation of metastasis induced by 
Inteileukin-1 or lipopolysaccharide in л human melanoma/nude mouse system 
Renato G.S. Chirivi1, Angela Garofalo1, Ines Martin Padura2, Alberto Mantovani2 and 
Raffaella Giavazzi1 
'Mario Negri Institute for Pharmacological Research, 
Via Gavazzeni 11, 24125 Bergamo, and JVia Eritrea 62, 20152 Milano, Italy 
This study examined the ability of the recombinant human interleukin 1 receptor 
antagonist (IL-lra) to block interleukin 1 (IL-l)-mediated experimental metastases 
from the A375M human melanoma. In vivo, IL-lra administrated at concentrations > 
200 times IL-1 significantly inhibited the increase in lung colonies induced by IL-1 in 
nude mice. The response to IL-1 was significantly inhibited when IL-lra was 
administered simultaneously with or 1 to 3 h before IL-1. In vitro, the incubation of IL-
1-activated endothelial cells with IL-lra prevented the increase in adhesion of A375M 
melanoma cells. At the same experimental conditions, IL-lra inhibited the augmented 
expression of the intracellular and vascular cell adhesion molecules 1 and E-selectin 
induced by IL-1 on endothelial cells. Lipopolysaccharide, an IL-1 inducer, increased the 
number of lung colonies in nude mice. IL-lra injected with or 1 h after 
lipopolysaccharide inhibited this augmentation, suggestinga role for host-produced IL-
1 in metastasis formation. 
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INTRODUCTION 
Altered production and response to cytokines have often been described in relation 
to malignancy Clinical and experimental reports have described tumor cell arrest and 
growth at sites of injury, healing and inflammation (1,2) The injection of nonspecific 
inflammatory stimuli may increase experimental metastases associated with the 
intravascular release of inflammatory mediators (3) We and others have shown that 
the injection of inflammatory cytokines, such as IL-1 and TNF, increased the number 
of metastases in different murine and human tumor models (4-9) 
A naturally occurring IL-lra has recently been identified and cloned (10-12) IL-lra 
binds to cellular IL 1 receptors and blocks several IL-1-mediated responses m vitro In 
animal models IL-lra provides protection against several pathological processes 
associated with inflammation For review, see Refs 13 and 14 
The present study investigated the effect of IL-lra on the augmentation of 
experimental metastases by IL-1 To assess the role of endogeneous IL-1 in metastasis 
formation, the effect of IL-lra on lung colonies induced by LPS was investigated 
MATERIAL AND METHODS 
Animals 
Female NCr-nu/nu mice were obtained from the National Cancer Institute Animal 
Program, Tredenck, MD, and used when 6 to 8 wk old Throughout the experiments 
mice were housed in a laminar flow cabinet and manipulated under aseptic 
conditions 
Cell cultuie 
The A375M human melanoma metastatic to the lungs of nude mice was 
maintained on plastic in Eagle's minimum essential medium supplemented with 10% 
fetal calf serum (4) Tumor cells were harvested by brief exposure to 0 25% trypsin 
0 02% EDTA, washed twice, and resuspended as indicated in the respective assays 
EC isolated from human umbilical vein as previously described (15) were 
maintained in medium 199 supplemented with 10% fetal calf serum and 10% new 
born calf serum, 5 μg/ml endothelial cell growth supplement, and 100μg/ml heparin 
All culture reagents were from Gibco, Paisley, Scotland 
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Reagents 
Human recombinant IL-lß (specific activity, 107 units/mg) was obtained through 
the courtesy of Τ Barlozzan (BASF, Bioresearch Corp , Cambridge, MA) and IL-lra was 
generously supplied by E Tracey, of the Upjohn Company, Kalamazoo, MI Aliquots of 
cytokines were stored at -80°C until injection LPS {Escherichia coli endotoxin stram 
055 B5) was from Sigma Chemicals C o , St Louis, MO Monoclonal antibodies to 
VCAM-1 (4B2), E-selectin (13D5) and ICAM-1 (11C8/1) were obtained through the 
courtesy of A Gearing (British Biotechnology, Ltd , Oxford, England) For EC treatment 
cytokines were diluted in Medium 199 The vehicle for injections was endotoxin-free 
PBS All treatments were given at the doses and schedules indicated in the "Results" 
Lung colonisation assay 
Single cell suspensions resuspended in Ca-^ Mg^-free Hanks balanced salt solution 
at the concentration of 5xl(W0 2 ml were injected ι ν in the lateral tail vein of nude 
mice (4) At autopsy, 6 wk later, lungs were fixed in Bouin s solution, and the number 
of tumor colonies was counted under a dissecting microscope Differences in the 
numbers of colonies were analyzed using the Mann-Whitney U test All the results on 
experimental metastases are representative of at least two independent experiments 
Adhesion assay 
EC grown to confluent monolayers in 96-well plates were washed twice and then 
activated for 4h with IL-1, IL-lra, or the combination of the two at concentrations 
indicated in the "Results" After incubation monolayers were washed twice and 
refilled with 50 μΐ Medium 199 containing 1% bovine serum albumin (test medium) 
Tumor cells were radiolabeled with f25I]-iododeoxyuridine (Amersham International, 
Amersham, United Kingdom) as described previously (15) Fifty μΐ of cell suspension 
(3xl04 cells) were added to each well containing EC previously treated with cytokines or 
medium alone and incubated for 30 min at 37°C After incubation, nonadherent cells 
were removed by careful aspiration and three washes with test medium Wells were 
incubated for 10 min with 200 μΐ of 0 IM NaOH and the lysate was counted in a 
gamma counter Results are expressed as the percentage of attached cells relative k> 
total addedcells Differences were analyzed by multiple comparisons using the Dunnett 
test 
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Flow cytometric analysis 
EC activated with cytokines as described above were harvested by brief exposure to 
0.25% trypsin-0.02% EDTA, washed twice, and resuspended in PBS with 2.5% US. The 
expression of adhesion proteins was determined by indirect immunofluorescence 
using a FACS-STAR-Plus (Beckton-Dickinson) (16). Briefly, after incubation with the 
appropriate primary antibody (1:50 dilution) in PBS with 2.5% HS for 30min at 4°C, 
cells were washed and incubated with an affinity-purified fluorescein isothiocyanate-
labelled goat anti-mouse immunoglobulin antiserum for 30 min at 4°C (Tecno 
Genetics, Milan, Italy). Results were expressed as percentage of positive cells and mean 
channel fluorescence intensity. 
RESULTS 
Effect of IL-lra on IL-1-indiiced increase in lung colonies 
We have reported that IL-1 (from 0.1 to 10 μg/mouse i.v), given before the injection 
of A375M tumor cells, significantly increased the number of tumor colonies in nude 
mice (4). Using the working concentration of 0.1 μg of IL-1 i.v. 4 h before tumor cells, 
we investigated the concentrations and schedules of IL-lra that counteracted this 
increase (Figs. 1 and 2). 
Lung colonies were significantly more numerous (median number, 268) in mice 
receiving IL-1 than in vehicle treated mice (median number, 62). IL-lra administrated 
simultaneously with IL-1 prevented this increase in a dose-dependent manner (Fig. 1). 
The inhibition was significant when a > 200-fold excess of IL-lra (> 20 μg/injection) 
over IL-1 was administered (median number of lung colonies, 83 and 29 in mice 
receiving respectively, 20 and 100 μg IL-lra). IL-lra alone (from 2 to 200 μg/mouse i.v.) 
before tumor cells did not significantly influence the number of lung colonies from by 
the A375 melanoma in nude mice (data not shown). 
Complete inhibition of lung colonies was achieved when IL-lra was injected 
together with IL-1 (Fig. 1) or 1 to 3 h before it (with tumor cells injected 4 h after IL-1) 
(Fig. 2). The median numbers of lung colonies were 23 and 6 in mice treated with IL-
lra 3 h and 1 h before IL-1, compared to 270 in IL-1-treated mice, while no inhibition 
was seen when IL-lra was given 24h before IL-1 (median number of lung colonies, 224) 
(Fig. 2). IL-lra has some effect even when given 1 or 3 h after IL-1 (tumor cells injected 
4 h after IL-1) (median lung colonies, respectively, 113 and 84) (Fig. 2). 
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Figure 1. Inhibition of the ÌL-1-
induced increase in lung colonics by 
IL-lra IL-1 (Ol ßg ¡mouse), alone, 
or together with IL-lra (4, 20, 100 
ßg/mouse) was injected i.v. together in 
a final volume of 0.2 ml 4 h before ι ν 
injection of 5x10s A375M melanoma 
cells Control mice (C) received the 
same volume of vehicle Autopsies 
were performed 6 wk later Results are 
the median number of lung colonies 
for each group (n=8). All mice 
presented lung colonies at autopsy *, 
P< 0 001 compared to lL-1-treated 
nuce 
Mouse treatment 
Inhibition of tumor cell adhesion to IL-l-activated EC by IL-lra 
Fig 3 shows that the adhesion of A375M melanoma cells was significantly increased 
on IL-l activated EC IL-lra added to IL-l during EC activation inhibits the increased 
adhesion of A375M melanoma cells (Fig. 3) In accordance with the ¡n vivo results, a > 
200-fold excess of IL-lra was needed to completely block the increment of tumor cell 
adhesion on IL-1-activated EC IL-lra added 1 and 4 h after IL-l did not prevent the 
increase of tumor cell adhesion on EC (data not shown) Resting EC incubated for 4 h 
with the same concentrations of IL-lra alone did not change their adhesivity for 
A375M cells (data not shown). 
To evaluate the relevance of adhesion molecules on the inhibition of tumor cell 
adhesion on activated EC, the effect of IL-lra on their expression was studied 
Treatment of EC with IL-l induced the expression of VCAM-1 and E-selectin and 
increased the expression of ICAM-1 on EC (Fig. 4) The addition of IL-lra inhibited IL-
1-induced expression of VCAM-1 and E-selectin and IL-l-augmented expression of 
ICAM-1 on EC (Fig. 4). The treatment of EC with IL-lra alone did not influence the 
expression of adhesion molecules on EC (data not shown) 
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relative to IL-1 injection 
Figure 2. Time cour^eof the inhibition of ¡L-1-induced lung colonies by IL-ira Nude mice were given 
IL-lra (20 ßglm ι v) at various times relative to the injection of IL-1 (0 1 ßg/mouse ι ν) A375M 
(5x10^ cells ι ν ) were given 4 h after ILA, and autopsies performed 6 wk later All mice presented lung 
colonies at autopsy (n=S) C, Control mice receiving no IL-1, ILI mue lecewmg IL-1 alone *, Ρ <0 001, 
**,P <0 005 compared to IL 1 treated mice 
80 -, 
С IL-1 І1 1 6 18 1 40 1 200 1 1000 
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Endothelium treatment 
Figure 3 Inhibition by IL-lra of 
tumor cell adhesion on IL-1-activated 
endothelial cells EC were treated with 
medium (C), IL-1 alone (2 ngfrnl), or 
IL-1 plus IL-lra for 4 h at 37°C before 
the adhesion assay Cell adhesion was 
evaluated after 30 min Coluns, mean 
of four replicates and are 
representative of one experiment of 
three done, SD *,P<001, ", P< 
0 05 compared to IL-1 -treated EC 
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Inliibttton of the LPS-mduced increase in lung colonics by IL-lra 
To assess the effect of IL-lra on endogeneous IL-1, studies were conducted in mice 
given injections of LPS Since IL-1 is expressed rapidly after in vivo injection of LPS 
(17), LPS-treated mice are useful for studying the roles of IL-1 and its antagonist in 
different biological responses 
As expected, LPS (1 μg/mouse ι v) given to nude mice 4 h before A375M tumor 
cells raised the number of lung colonies (median number, 165) compared to vehicle-
treated mice (median number, 46) (Fig 5) Injection of IL-lra (100 μg/dose) together 
with LPS inhibited this increase (median number of lung colonies 62) IL-lra given 1 h 
after LPS (3 h before tumor cells) completely prevented the increase in lung colonies 
(median number, 49) (Fig 5) 
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Figure 4 Effect of IL-lra on IL-1 -induced expression of adhesion molecules on EC 
EC were treated with medium, (C), IL-1 alone (2 ng/ml), or IL-1 plus IL Ira for 4 h at V°C before 
cytometric analysis Results are the percentage positive cells and the mean channel of fluorescence intensity 
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DISCUSSION 
Our previous work showed that IL-1 treatment induced the increase of lung 
metastases in different tumor systems (4,5). The study described here shows that this 
augmentation can be inhibited by IL-lra Since treatment with IL-lra inhibits LPS-
lncreased experimental metastasis formation, these results also indicate that IL-lra 
inhibits metastasis augmentation induced by host- produced IL-1 
The inhibition of lung colonies was dose dependent, showing a significant effect 
when IL-lra was given at least 200-fold in excess over IL-1 In other experimental 
models a large excess of IL-lra (102 to 104-fold) is generally required to reduce by 50% or 
block the biological response to IL-1 (13,14) It has been suggested that, although IL-1 
and IL-lra bind to receptors with approximately the same affinity (10), probably only a 
few IL-1 receptors are necessary to elicit the biological response to IL-1 and, therefore, 
higher concentrations of IL-lra are needed to saturate the IL-1 receptors and achieve 
antagonism (18) The effect of IL-lra was time dependent and, consistently with the 
kinetics of IL-1 lung colony induction (4), the inhibitory effect was achieved when IL-
lra was injected together or shortly before or after IL-1, but not 24 h before 
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Figure 5. Inhibition by IL-lra of the 
LPS-mduced increase tn lung colonies 
Nude mice were treated with LPS (1 
μg|mouse ivi 4 h before the injection of 
5x10^ A375M cells tv IL-lra (100 
ßg/mouse) was injected together with 
LPS or 1 hour after it m о final volume 
of 0 2 ml Control mice (C) received the 
same volume of vehicle Autopsies were 
performed 6 wk after tumor cell 
injection Results are the median numbet 
of lung colonies for each group (n=8) 
All mice presented lung colonies at 
autopsy *, Ρ <0 001 compared to LPS-
treated mice 
Several mechanisms associated with response to cytokines may be resposible for 
metastasis formation (19) Metastasis is a complex multistep process that requires to 
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circulating tumor cells to extravasate into specific metastatic sites The interaction of 
metastatic cells with the microvasculature is a crucial step in tumor cell arrest at the 
capillary bed of secondary organs (20,21) Inflammatory cytokines such as IL-1 and TNF 
activate specific adhesive mechanisms on EC, resulting in increased adhesiveness for 
different human tumor cells (15,22,23) In this study we show that IL-lra inhibits the 
increased adhesion of A375M melanoma cells on IL-1-activated EC, further supporting 
that IL-1-mediated tumor/EC interaction is involved in the metastatic process 
Moreover, in agreement with recent findings obtained using the intracellular form of 
IL-lra (24), we show inhibition of adhesion protein expression on EC surface by IL-lra 
Specific adhesion proteins have been shown to mediate tumor cell adhesion on 
activated EC Among the others VCAM-1 appears to play an important role in 
melanoma adhesion on activated EC (25,26) including A375M melanoma cells (R 
Giavazzi, unpublished observation) Our results showing inhibition of VCAM-1 and 
other adhesion protein expression on EC surface by IL-lra suggest that IL-lra inhibits 
tumor cell adhesion by preventing augmented expression of adhesion molecules on 
EC surface 
IL-lra alone did not significantly influence the number of lung colonies by the 
A375M melanoma in nude mice, it affects neither A375M tumor cell adhesion nor the 
expression of adhesion molecules on EC surface (data not shown) Thus, IL-lra alone 
has no agonist effect on metastasis formation even at a high concentration, supporting 
its function as a pure antagonist (10) However it is worth noting that large excess of IL-
lra further inhibits the number of colonies in IL-1- treated mice compared to control 
mice (Fig 1) and tumor cell adhesion on IL-1-activated EC (Fig 3) These effects, albeit 
not significant, were reproducible in different experiments One could speculate that 
direct or indirect host- or tumor cell- produced cytokine could mediate those 
phenomena Indeed, tumor cells expressing and producing IL-1 have been described 
(27,28), and IL-1-producing melanomas may induce the expression of adhesive 
molecules on EC and increase tumor-EC adhesion (29) 
Increased tumor cell retention and more metastases after IL-1 and TNF treatment 
have been described in different animal tumor models (4-6,8,9,22) However, all these 
studies were conducted with exogenous cytokine administrated to mice, so the 
significance of these findings in the pathophysiology of cancer metastasis is 
questionable While recent resports showed a contribution of tumor-induced TNF in 
tumor malignancy (7,8), there is no information on the role of endogenous IL-1 in 
metastasis LPS is a nonspecific inflammatory stimulus that triggers a cascade of host-
derived mediators responsible for its proinflammatory effects IL-lra appears to 
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improve endotoxin-toxic effects due to IL-1-mediated acute inflammation (30-32) 
Since IL-lra specifically binds IL-1 receptors, our results showing that IL-lra inhibits 
LPS-induced increase of lung colonies indicate that host-producted IL-1 plays a pivotal 
role in this increase. 
In conclusion, we have shown that IL-lra blocks two aspects of the metastatic process 
modulated by IL-1: the increased tumor cell adhesion on EC and lung colony 
formation. The inhibitory effect of IL-lra on the increase in artificial metastasis 
induced by LPS suggests that endogenous IL-1 plays a role in promoting malignancy. 
Increased synthesis and release of cytokines, including IL-1, have been reported in 
neoplastic diseases (33), but their contribution to the malignant behavior of tumor cells 
is not clear The effects of IL-1 antagonists on the malignant behavior of IL-1-inducing 
tumor cells merit further investigation. 
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We have previously reported that treatment with interleukin-1 (IL-1) induced the 
augmentation of lung tumor colonies by a human melanoma in nude mice. Here we 
have investigated the involvement of the n4ßl integrin, the very late antigen-4 (VLA-
4) in this augmentation. 
A375M melanoma cells expressed high levels of VLA-4 and preferentially adhered 
to a surface coated with vascular cell adhesion molecule-KVCAM-1), the ligand for 
VLA-4 on activated endothelial cells. This adhesion was inhibited by treating tumor 
cells with saturating concentration of monoclonal antibody (mAb) to VLA-4. The 
production of lung colonies was significantly enhanced in nude mice given an 
injection of IL-1 before A375M melanoma cells. Immunoperoxidase staining showed 
that VCAM-1 could beexpressed on lung vascular endothelium of mice in response to 
IL-1. Pretreatment of melanoma cells with a mAb to VLA-4 completely abrogated the 
IL-1-induced augmentation of lung colonies. Using two metastatic melanoma clones 
(clones 2/4 and 2/60) that expressed different levels of VLA-4, we found that only 
VLA-4 bearing cells adhered to a VCAM-1 coated surface and formed enhanced 
numbers of lung colonies in IL-1 treated nude mice. This augmentation was inhibited 
by pretreating the tumor cells with anti-VLA-4 mAb. 
These results demonstrate, in vivo, the functional involvement of VLA-4 on 
melanoma cells in IL-1-mediated lung colony augmentation, most probably involving 
Hie interaction of tumor cells with VCAM-1 on activated endothelial cells. 
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INTRODUCTION 
The arrest of tumor cells in the capillary bed of secondary organs requires the 
interaction of tumor cells with vascular endothelium Different tumor and FC surface 
adhesion molecules have been proposed to mediate this interaction, but their specific 
role in metastasis still needs to be elucidated (1,2) Several pieces of evidence suggest 
that the activation status of EC influence tumor cell adhesion and metastasis 
formation (3) Cytokines, such as IL-1 and TNF, increase the expression of adhesion 
molecules on the EC surface resulting in increased adhesion of tumor cells (4-6) IL 1 
and TNF have been shown to augment tumor spread and metastases in different 
tumor models (6-10) Using monoclonal antibodies against specific adhesion molecules 
on FC or counter-receptors expressed on the tumor cell surface preferential adhesion 
pathways have been shown to be used by different tumor types (11,12) Thus the 
adhesion of melanomas, but not colon carcinoma cells, to activated EC appeared to be 
mediated by the cytokine-inducible adhesion molecule INCAM 110, later identified as 
VCAM-1 (11) The functional dominant receptor for VCAM-1 in melanoma cells has 
been identified as the mtegnn VLA-4(a4ßl) (13) It has been shown that se\eral 
malignant melanoma cell lines adhere in vitro to cytokine aclivated EC via VLA 
4/VCAM-l interaction (11,14) Although these findings strongly suggest that the 
enhancement of metastases by cytokines could be due to VCAM-1 /VLA-4 mediated 
adhesion, no direct evidence on the specific role of these adhesion molecules in 
metastasis formation, in vivo, has been shown 
In the present study we investigated the effect of a mAb to VLA-4 on the 
augmentation of human melanoma experimental metastases induced by IL 1 
treatment in nude mice To assess the involvment of VLA-4 in this augmentation tht 
ability to form lung colonies in IL-1 injected mice was investigated with melanoma 
clones that express different levels of VLA-4 
MATERIALS AND METHODS 
A minai* 
Temale NCr nu /nu nude mice were obtained from the National Cancer Institute 
Animal Program, Frederick, MD and used when 6-8 weeks old Throughout the 
experiments mice were housed in laminar flow cabinets and manipulated under 
aseptic conditions 
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Cell culture 
The human A375M melanoma (8) and two clones 2/4 and 2/60(15), derived from η 
human melanoma metastasis (Mel 665/2), were maintained in culture as described in 
the respective references. Tumor cells were harvested by brief exposure to 0.25% 
trypsin-0.02% EDTA, washed twice and resuspended as indicated below. 
Reagents and antibodies 
Human recombinant IL-lß (sp act. 107U/mg) was provided by BASF, Bioresearch 
Corp, Cambridge, MA Recombinant soluble proteins, VCAM-1 (16) and E-selectin (17) 
were obtained from Dr J. Clements (British Bio-technology Ltd., Oxford, England) 
Purified murine anti VLA-4 (a4 chain, sub-class IgGl) mAb(clone 2B4) (18) and (clone 
IIP1/2)(19) were used for in vitro and in vivo blocking studies An isotype matched 
control mAb (clone 2H4) was produced against a recombinant variant of the yeast Ту 
element (TY-VLP). Murine anti-ICAM-1 (sub-class IgGl) mAb (clone BBIG-I1) was from 
R and D Systems, Abingdon,U К Murine anti-VLA-5 («5 chain, IgG2b) mAb (clone 
SAM-1) and rat IgG2a anti-VLA-6 (<i6 chain, IgG2a) mAb (clone GoH3) were from 
Immunotech, Marseilles, France. Murine anti-ßl chain (IgGl) mAb (clone 4B4) and 
anti-lH chain (lgG2a) mAb (clone т А Ь І З ) were respectively from Coulter 
Immunology, Hialeah, Florida and Becton Dickinson, San Jose, Ca. Rat anti-mouse 
VCAM-1 (IgG2b) mAb (clone M/K1.9) was obtained from ATCC. 
Flow cytometric analysis 
The expression of adhesion molecules was determined by indirect 
immunofluorescence. Tumor cell suspensions obtained as described above were 
incubated with the appropriate primary mAb in PBS with 2% HS for 30min at 4°C 
Cells were then washed and incubated with an affinity-purified FITC-labelled goatanli-
mouse (Tecno Genetics, Milan, Italy) or rabbit anti-rat (BIO-Yeda, Rehovot, Israel) 
immunoglobulin antiserum for 30min at 4°C. Fluorescence was measured using a 
FACS-STAR-Plus (Beckton-Dickinson) Results were expressed as percentage posili\ e 
cells, and mean channel fluorescence intensity on a linear scale 
Adhesion assay 
Ninety-six-well Pro-Bind assay plates (Falcon) were coated with soluble VCAM-1 or 
E-selectin by adding 50μ1 of protein ^ g / m l unless otherwise indicated) and 
incubating overnight at 4°C. After two washes in PBS, coated surfaces were incubated 
for one hour with PBS containing \°/< BSA and then used for the adhesion assay 
44 
Control wells were coated with buffer only, following the same procedure Tumor cells 
radiolabeled with [125]-Iododeoxyundine (Amersham International, Amersham UK) 
as described previously (4) were preincubated for 30min at 4°C in culture medium with 
0 2% BSA(test medium) or in test medium containing concentrations of mAb from 0 1 
to 10^ig/ml After washing, ΙΟΟμΙ of these cells (3xl04 cells) was added to each well and 
incubated for 30min at 37°C After incubation non-adherent cells were removed by 
careful aspiration and three washes with test medium Wells were incubated for lOmin 
with ΙΟΟμΙ of 0 IM NaOH and the lysate was counted in a gamma counter Adhesion 
was expressed as the percentage of attached cells relative to total cells added 
2 4 6 8 
Protein (дд/ті) 
1 1 
Anti-VLA-4 (цд/ті) 
Figure 1 Anti VLA 4 mAb inhibits melanoma cell adhesion to VCAM Ì A) Melanoma cells were 
added to wells coated with different concentration of purified VCAM 1 and E selectin B) Melanoma celL 
wei e pi ctieatid with set ¡ally diluted concentrations of anti VLA 4 (2B4) niAband then added to VCAM 
1 coatLti surface (5μ$/ηιΙ) Results repiesent the percentage of attached cells relative to total cells added 
Em /i point i Í pi esents the mean ± SD of triplicates 
Lung colonisation assay 
IL-1 at the concentration indicated in the results was administered in 0 2ml 
endotoxin-free saline in the lateral tail vein (i v) of nude mice 4 hour before tumor 
cells Control mice received the same amount of vehicle Tumor cells were pre-
incubated with antibodies (2xl06 cells with l(Vg mAb) for 30min at 4°C in PBS 
containing 2% HS Control cells were pre-incubated in PBS HS After washing, tumor 
cell suspensions (viability > 85% by trypan blue exclusion) were resuspended in 
Ca"Mg"-free Hanks balanced salt solution at concentrations of 5xl05 or lx l0 6 /0 2ml 
and were injected ι ν in nude mice (8 mice/group) To verify their tumongenicity, the 
same preparation of tumor cells, was injected s с in 3 additional nude mice At 
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autopsy, lungs were fixed in Bouin's solution and the number of tumor colonies was 
counted under a dissecting microscope. Differences in the numbers of metastases were 
analyzed using the Mann-Whitney U test. 
Table 1. Inhibition of A375M cell adhesion to VCAM-1 
Tumor cell treatment3 
anti-ßl integrin 
anti-ßl integrin 
anti-a4 integrin 
anti-a4 integrin 
anti-a5 integrin 
anti-a6 integrin 
anti-ICAM-1 
anti-TY-VLP (irrelevant) 
Clone 
4B4 
Mab 13 
2B4 
HP 1/2 
SAM-1 
GoH3 
BBIG-I1 
2H4 
Relative binding 
(% 
to VCAM-1 
control ± SD)b 
10 8 + 0.7 
8.8 ±1.3 
5.2 ±1.5 
7.7 ±0.6 
99 8 ± 1 1 
97 5 + 3 2 
99 8 ± 2.0 
89.2 ±1.6 
a) Tumor cells were premcubated with saturating concentrations (determined by 
FACS analysis) of antibodies before the adhesion assay 
b) Numbers represent the percentage of binding relative to the control with no 
antibody (mean of three replicates ± SD). The percentage of A375M melanoma 
cell adhesion to VCAM-1 (5ßg/ml)-coated substrates was 79 4 ± 5.1 m 5 
different experiments. 
Immunohistochcmistry 
Lungs were removed from nude mice 4h after the injection of saline or IL-1 as 
described above, immediately frozen, cut at 3 mm of thickness and fixed in acetone 
Immunostaining procedure was performed using ABC method (ABC -Elite, Vectastain, 
Vector Burlingame, Cn). Briefly, sections were treated with 0,3% 1I202 in methanol toi 
quenching the endogenous peroxidase, air dried and incubated with: 1) a blocking 
solution containing rabbit serum, BSA and triton X-100 in PBS 0.01M, pH=7.4 for 
30min at room temperature; 2) mAb to VCAM-1 at 4° С overnight; 3) biotinylated-
rabbit-anti-rat-IgG mouse-adsorbed after a washing in PBS; 4) ABC solution for 30min 
at room temperature after another washing step The reaction was developed using 
diaminobenzidine (DAB-tablets, Merck) in H20 additionated with 0.1% H 2 0 2 . Negative 
controls were obtained by omission of the primary antibody The analisys of the 
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sections was done by a photomicroscope (DM RB, Leitz Wetziar, Germany) connected 
by a videocamera (CCD Ins, Sony, Japan) to a video (Trinitron Color Video monitor, 
Sony, Japan) and a laser printer (Color Video Printer Mavigraph, Sony, Japan) 
RESULTS 
Inhibitory effect of anti-VLA-4 on melanoma cell adhesion to VCAM-1 
The adhesive proprieties of A375M melanoma cells were studied on plastic surface 
coated with soluble adhesion protein Fig 1A shows that A375M cells adhere to 
immobilized VCAM-1 protein whereas E-selectin does not support their adhesion The 
adhesion was concentration dependent and reached a plateau at 5pg/ml protein To 
demonstrate that the binding was dependent on VLA-4/VCAM-1 interaction, a mAb 
to VLA-4 was used (Fig IB) The incubation of tumor cells with a mAb to the a4 chain 
of the integnn VLA-4 (clone 2B4) inhibited the adhesion of these cells to VCAM-1 in a 
concentration dependent manner Both the anti «4 mAbs (clone 2B4 and clone HP1/2) 
produced greater than 90% inhibition (Table 1) As expected the treatment of tumor 
cells with a mAb to ßl chain showed a similar blocking effect (Table 1) In contrast the 
treatment of tumor cells with mAbs to the n5 chain of the integnn VLA-5 and a6 chain 
of the integnn VLA-6 or to ICAM-1 did not affect their adhesion to VCAM-1 coated 
surface (Table 1) 
Inhibitory effect of anti-VLA-4 on IL-1 induced augmentation of lung colonies 
Having found the concentration of mAb to VLA-4 that blocked melanoma cell 
adhesion to VCAM-1 we evaluated the effect of mAb to VLA-4 on the ability of tumor 
cells to produce metastases in IL-1 treated nude mice The pretreatment of A375M cells 
v\ilh mAb to VLA-4 (clone 2B4) completely abrogated their ability to form a higher 
number of lung colonies in IL-1 treated mice (Fig 2) The median number of lung 
colonies decreased from 44 to 10 and from 130 to 17 in mice given 0 1 and ìμg IL-1 
respectively (Fig 2) The treatment of tumor cells with anti-VLA-4 mAb did not 
influence their intrinsic metastatic ability as indicated by the number of lung colonies 
in mice given vehicle or a suboptimal dose of IL-1 where mAb treated and-untreated 
cells formed similar number of lung colonies (Fig 2) The inhibition was not due to 
cytotoxicity of the antibody since the incubation of the melanoma cells with mAb did 
not affect the viability of tumor cells Moreover mAb-treated tumor cells injected s с 
in nude mice produced tumors at the same rate as untreated tumor cells (data not 
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shown). 
Similar results were obtained treating tumor cells with a different anti-VLA-4 
mAb. Table 2 shows that the two different mAbs to VLA-4 integrin expressed on 
A375M cells, clone 2B4 and HP 1/2, have similar effect producing respectively 92% and 
84% inhibition of lung colonies in IL-1 treated mice compared to vehicle treated mice 
The treatment of melanoma cells with isotype matched control mAb (clone BBIG-I1) to 
ICAM-1 or an irrelevant mAb (clone2H4) did not significantly affect the formation of 
lung colonies by A375M melanoma cells (Table 2). 
Treatment with antibodies against other ßl integrms expressed by melanoma cells 
revealed that only mAb against VLA-4 (a4 chain) significantly affected IL-1-
augmentation of lung colonies Table 2 shows that the treatment of tumor cells with 
saturating concentrations (asdetermined byFACS analysis) of anti-VLA-5 (a5 chain) or 
VLA-6 (a6 chain) mAb did not affect the augmented production of metastases in mice 
receiving IL-1 
S- anti-VLA-4 
3+ anti-VLA-4 
S. 150 
с 
га 
IL-1 t reatment (μς) 
Figure 2. Anti-VLA-4 mAb inhibits IL-1 induced augmentation of lung colonies. A375M melanoma 
cells (5xW5) premcubated with or without anti VLA-4 (2B4) mAb were injected in nude mice given IL-1 
(0.01-lug/mouseli.v) or vehicle 4 hours before. Autopsies were performed six weeks later. Results are the 
median number of lung colonies for each group (N=S) All mice presented lung colonies at autopsy *P < 
0 007. 
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Tabid. Antibodies against VLA-4 integrin inhibit lung colony 
enhancement ¡n IL-1-treated mice 
Antibody treatment % Positive cells Median no. of lung 
Experiment to (clone)·1 (mean fluorescence)13 colonies (range)0 
None 
VLA-4 (2B4) 
ICAM-1 (BBIG-I1) 
TY-VLP(2H4) 
None 
VLA-4 (HP 1/2) 
VLA-5 (SAM-1) 
VLA-6 (GoH3) 
3.2 (530) 
86.2 (462) 
98(511) 
8.5 (434) 
8.2 (349) 
90(317) 
95 (300) 
87 (298) 
138 (35-235)d 
11 (2-44)c 
104 (42-229) 
82 (35-193) 
150 (48-294)d 
25 (5-54)e 
157(54-206) 
186 (66-245) 
a) Tumor cells were premcubated with monoclonal antibodies as described in the "Material and 
Methods " Results are representative of two independent experiments 
b) Surface expression was quantified by flow cytometry. Control treated (none) refers to treatment 
only with secondary fluorescematcd antibody. 
c) Nude mice were treated with 0.5 ßg IL-1 4h before tumor cell injection (5дг7()\) and autopsied 6 
weeks later. N=8 each group 
d) The median number of lung colonies m vehicle treated mice was 5 (range, 2-25) and 8(range, 3-
37),respectively, m experiment 1 and 2 
e) p=0 001 compared to mice receiving control treated cells (none) 
Expression of VCAM-1 on lung vascular endothelium 
Immunohistochemical staining with anti-VCAM-1 showed that VCAM-1 was 
induced on lung vascular endothelium of mice injected with ^ g IL-1 and biopsied 4 h 
later (Fig. ЗА). Mice receiving O.^g IL-1 showed only a weak positivity in the same 
region (data not shown) In contrast VCAM-1 was undetectable on lung vascular 
endothelium of nude mice receiving O.O^g IL-1 (Fig 3B) as in control nude mice 
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receiving vehicle alone (data not shown). 
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Figure 3. Immunoper oxidase staining with mAb to VCAM-1. A) Lung sectionfrom mice given 1 ßg 
of 1L-1 with marked airway vascular endothelium. B) Lung section from mice given 0.01 ßg ¡L-Î. С) and 
D) correspondent negative controls. 
Adhesive and metastatic properties of melanoma clones with different VLA-4 profiles 
To further investigate the relevance of VLA-4 expression on melanoma cells to IL-1 
enhanced hematogeneous metastases, we have investigated the adhesive and 
metastatic properties of two clones derived from the same melanoma (Table 3). Clone 
2/4 express high level of VLA-4 on the cell surface, while clone 2/60 is almost 
completely negative for VLA-4 (Table 3). Only clone 2/4 adhered to VCAM-1 coated-
surface (79% attached cells), while clone 2/60 did not adhere to VCAM-1 coated surface 
(3% cells) (Table 3). The adhesion of clone 2/4 to VCAM-1 was significantly inhibited by 
pre-treating tumor cells with anti-VLA-4 mAb (clone 2BA). Both clones were equally 
low metastatic in untreated nude mice as shown by the number of lung colonies 
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following i.v. injection of tumor cells (median lung colonies respectively 1 and 5 for 
clones 2/4 and 2/60). However in nude mice given IL-1 only the 2/4 clone produced a 
higher number of lung colonies (median number of lung colonies was 20 comparing 
to 1 in vehicle treated mice) (Table 3). This augmentation was blocked when tumor 
cells were pre-treated with the anti-VLA-4 mAb (the median number of lung colonies 
decrease to 3 ). 
Table 3. Adhesive and metastatic properties of Mel 66512 melanoma clones 
Melanoma clone 
(treatment)3 
2/4 (medium) 
2/4 (+anti-VLA-4) 
2/60 (medium) 
2/60 (+anli-VLA-4) 
FACS 
analysis15 
7.6(430) 
95(539) 
7.2(314) 
11(325) 
Adhesion to 
VCAM-1C 
79 ±1.54 
25 ± 5.26 
3.4 ± 0.82 
0 
Lung 
+vehicle 
1 (0-4) 
4(0-15) 
5(1-10) 
4(2-7) 
colonies'1 
+IL-1 
20 (16-25)° 
3(0-5) 
5(0-9) 
9(0-15) 
a) Tumor cells were preincubated with medium alone or anti-VLA-4 mAb (2B4) as described in the 
"Material and Methods " for each assai/. Results are representative of two different experiment. 
b) Residís are the percentage of positive cells with mean chanci of fluoresccnse intensity. Control 
cells (medium treated) refers to treatment only with secondary fluorcbceinated antibody. 
c) Percentage of tumor cells attached to VCAM-1- coated substrate. Results are the mean of three 
replicates ± SD. 
d) Nude mice were treated with 1 pg IL-1 4h before tumor cells injection (IxW6) and autopsied 3 
months later. Results are the median number with range of lung colonies for each group (N=8). 
e) ρ < 0.001 compared to vehicle treated 
DISCUSSION 
In this study we have examined the involvement of the integrin VLA-4 (a4ül) 
expressed by human melanoma cells (the A375M and two clones of Mel 665/2) in the 
augmentation of experimental metastases induced by IL-1. We found that melanoma 
lines expressing a high level of VLA-4 were highly metastatic in nude mice upon 
administration of IL-1 and the treatment of tumor cells with mAb to VLA-4 inhibited 
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this augmentation The adhesion of these melanoma cells is augmented on cytokine 
activated EC and this increment has been shown to be mediated by the induction ol 
VCAM-1 on EC (14,20) Here we confirm that melanoma cells expressing VLA 4 
preferentially adhere to immobilized VCAM-1 protein The treatment of tumor cells 
with anti-VLA-4 mAb inhibited the adhesion of these cells to VCAM-1, indicating thai 
the attachment of melanoma to VCAM-1 was indeed mediated by VLA-4 expressed on 
the cells 
The treatment of A375M tumor cells with anti VLA-5 (a5ßl) and VLA-6 (a6Gl) 
mAb did not affect their adhesion to VCAM-1 coated surface nor the augmentation ol 
lung colonies These data indicate that the inhibitory activity of anti-VLA-4 mAbs is 
not a common property of anti-VLA integrin antibodies VLA-5 and VLA-6 act as 
fibronectin and laminin receptors respectively and are expressed in significant 
amounts on A375M cells (Table 2) The lack of effect of mAbs directed to these 
molecules suggests that tumor cell interaction with the endothelial matrix does not 
play a relevant role in IL-1 induced augmentation of metastasis Indeed, we have 
previously shown that IL-1 activation of endothelial monolayers does not cause 
retraction and exposure of the extracellular matrix {in viti υ and in vivo) and 
antibodies directed to fibronectin and laminin do not block the augmented adhesion ol 
tumor cells to EC (4,8) Overall these findings strongly suggest that the increased 
number of melanoma metastases after IL-1 treatment is mediated by the interaction of 
VLA-4 with VCAM-1 and does not involve direct interactions with the extracellular 
matrix A cascade of adhesive mechanisms has been proposed during the metastatic 
process The possibility that other adhesion mechanisms alone or in combination pia) 
a role in different phases of tumor endothelium/ matrix interaction deserves further 
studv 
In this study we also show the treatment of melanoma cells with mAb anli-ICAM-1 
did not significantly affect the formation of lung colonies byA375M melanoma cells m 
IL-1 treated nude mice (Table 2) ICAM-1 is highly expressed on melanoma cells and its 
expression has been often associated with their malignant phenotype (21,22) Our 
results indicate that its expression on melanoma is not directly involved in the 
augmentation of metastases mediated by cytokine activation of EC 
It has been shown that the enhanced adhesion of melanoma cells to cytokine 
activated EC correlated with their VLA-4 expression (14) This augmentation was 
inhibited by treating EC with anti VCAM-1 mAb or tumor cells with anti-VLA-4 (14) 
thus suggesting a role of these adhesion molecules in the interaction of melanoma 
cells with activated endothelial cells Here we have found that only melanoma cells 
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(clone 2/4) that express VLA-4 but not melanoma cells (clone 2/60) that do not express 
VLA-4, indeed adhered to a VCAM-1 coated-surface Both clones were equally 
metastatic in untreated nude mice as shown by the number of lung colonies following 
ι ν injection of tumor cells, but only the 2/4 clone produced more lung colonies in 
nude mice given IL-1 Also with this melanoma model the adhesion to VCAM-1 and 
the augmentation of lung colonies was inhibited by pre treating tumor cells with anti 
VLA-4 mAb In a recent study Kawaguchi and co workers showed that a higher 
number of fibrosarcoma cells overexpressing VLA-4 were detected in the lung of mice 
receiving TNF, but this did not correspond to an enhancement of metastases 
formation (23) As the authors suggested, EC binding is only the first step and other 
factors such as binding to subendothelial components are critical to establish 
metastasis Clone 2/60 binds to laminin and fibronectin suggesting that these cells 
have a number of the properties necessary to complete the extravasation process (15) 
Indeed clone 2/60 cells (not expressing VLA-4), are able to produce lung colonies in 
nude mice, albeit in low numbers However it seems possible that the lack of VLA-4 
limits their metastatic potential at least in mice treated with IL-1 
While this study was in progress a report (24) showed an inverse correlation with 
the expression of the integrin VLA-4 and the invasive potential of the murine B16 
melanoma cell line, thus proposing a negative role for VLA-4 in melanoma 
metastasis These results are only apparently in conflict with our study In fact in the 
report byQian et al (24) the expression of VLA-4 is associated with the suppression of 
spontaneous metastases (sc injection) and invasion in the matngel assay in vitro bul 
it does not affect local tumongenicity or experimental metastases (ι ν injection) As the 
above authors point out, their study was conducted in mice that do not express 
VCAM 1 In our studies only mice receiving IL-1 or other cytokines (8) that induce 
VCAM-1 on vascular endothelial cells show a higher number of lung colonies and 
similarly we found the treatment of melanoma cells with mAb to VLA-4 did not 
interfere with their ability to form lung colonies in control mice not receiving IL-1 
(1 ig 2 and table 3) The metastatic process comprises different steps such as detachment 
from primary tumor, invasion of extracellular matrix and extravasation, then the 
arrest in the blood vessels of the secondary organ is followed by extravasation, 
colonization and proliferation Together these studies suggest that integrins, ι e VLA-4 
can pia) a different role in different metastatic steps 
Although no direct evidence is given for VLA-4 mediated melanoma adhesion lo 
1С in \ n o , its role in IL-1 enhanced hematogenous metastases is supported by several 
pieces of evidence The adhesiveness of melanoma cells to cytokine activated EC 
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correlate with their VLA-4 expression and it is blocked by mAb to VLA-4 (14) Here we 
have shown that only melanoma cells expressing VLA-4 form a higher number of 
lung colonies in IL-1 treated mice (Table 3) On the other hand VCAM-1, a ligand for 
VLA-4 on activated endothelial cells,is rapidly induced in vivo on lung vascular cells 
in mice injected with IL-1 (Fig 3) whereas in vitro the treatment of melanoma cells 
with mAb to VLA-4 blocked their adhesion to VCAM-1 (Fig 1) It is therefore likely 
that the antimetastatic effect of anti-VLA-4 is related to its anti-adhesive effects 
Other cytokines such as TNF produce a similar effect on augmentation of metastasis 
(8,10,25) In support of our study a recent report showed that the TNF- induced 
augmentation of lung colonies by the murine B16-BL6 melanoma in syngeneic mice 
could be abolished by the treatment of tumor cells with a mAb to VLA-4 (25) In the 
same study the administration of mAb to VCAM-1 to the mice partially blocked the 
augmentation of lung colonies by TNF, thus providing direct evidence of the 
involvment in vivo of VCAM-1 in this augmentation (25) These results, though 
obtained with a different cytokine and with a murine tumor model, indicate thai the 
interaction between VLA-4 on tumor cells and VCAM-1 on lung endothelium is 
involved in cytokine enhancement of metastases 
In conclusion we show that high expression of VLA-4 is associated with the 
augmentation of lung colonies induced by IL-1 by two different human melanomas in 
nude mice and that this augmentation can be blocked by treating tumor cells with anti-
VLA-4 mAb These findings provide direct evidence for a role of VLA-4 in the 
cytokine-augmentation of lung colonies by melanoma The anti-adhesive properties of 
the anti-VLA-4 mAb strongly support a role for VLA-4/VCAM-1 dependent pathway 
as a major mechanism in IL-1-enhanced melanoma metastases Altered production 
and response to cytokines often occur in patients with malignant tumors EC 
activation with increased expression of adhesion molecules may results from cytokine 
released by reactive host inflammatory cells (26,27) We have recently shown that 
endogenous produced IL-1 caused the enhancement of experimental metastasis by 
A375M melanoma (28) Tumor cells themselves can also release cytokines including 
IL-1 and TNF, that in turn might stimulate tumor-EC adhesion (29) or cause 
augmentation of metastases (30,31) A treatment that interferes with these interactions 
might represent a useful tool to prevent the augmentation of metastases 
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The interleukin-lra (IL-1) gene was introduced by retroviral gene transfer into the 
A375P human melanoma cell line. Two hygromycin resistant colonies, colony-3 and 
colony-6, which respectively do not and do express and release II-1, were selected on 
the basis of Northern blot and ELISA. Both colonies adhered to resting human 
endothelial cells (EC) to the same extent. Pre-treatment of EC for 6 hr with conditioned 
medium (CM) from colony-6, but not from colony-3, increased the adhesion of A375P 
melanoma and HT-29 colon- carcinoma cells to EC. This increase was blocked by 
adding interleukin-1-receptor antagonist (IL-lra) to the EC monolayer. Treatment of EC 
with colony-6-СМ increased the expression of intercellular-adhesion molecule 1 
(ICAM-1), vascular-cell-adhesion molecule 1 (VCAM-1) and E-selectin. Co-cultivation 
of colony-6, but not colony-3 melanoma cells, with EC caused time-dependent 
increased expression of these adhesion proteins, reflecting their kinetics of expression 
on EC. Treating the EC with monoclonal antibodies to VCAM-1 and E-selectin 
abolished the colony-6-CM-induced increase in adhesion respectively to A375P 
melanoma and HT-29 colon carcinoma cells. In vivo, i.v. injection of colony-6 cells in 
nude mice increased the expression of VCAM-1 on lung microvascular EC. The 
retention of radiolabeled A375P melanoma cells in the lung was increased in nude 
mice primed with colony-6 cells, but not with colony-3 cells, injected 6 hr earlier. These 
results demonstrate that IL-1 produced constitutively by transformed A375P melanoma 
cells is functionally active, inducing adhesion molecules on EC that enhance their 
adhesiveness for tumor cells and increase tumor-cell retention in the lung of nude 
mice. 
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INTRODUCTION 
Interaction between tumor and endothelial cells (EC) is considered to be a crucial 
step in hematogenous tumor metastasis. Formation of blood-borne metastases requires 
the arrest of tumor cells in the vasculature, forming a barrier between circulating 
tumor cells and the parenchymal tissue of secondary organs This interaction is 
mediated by cell surface adhesion molecules (CAM) expressed on EC and tumor cells 
(1,4). Cytokines, such as interleukin-la (IL-I)and tumor necrosis factor (TNF), increase 
the adhesion of tumor cells to EC (11,23) through the induction or increased expression 
of several adhesion molecules on EC (5), which different tumor types use selectively to 
adhere to EC (19,24). These cytokines thus increase tumor spread and metastases in 
vivo in different human and murine tumor models (2,3, 22) 
Studies from a number of laboratories, including ours, have shown that IL-1-
activated EC promote the adhesion of melanoma cells, mainly through the over-
expression of vascular cell adhesion molecule 1 (VCAM-1) on cytokine-treated EC 
recognizing as a major receptor the a4ßl [very late antigen-4 (VLA-4)] integrin on 
melanoma cells (13,20,24). Moreover, exogenous IL-1 as well as host-induced IL-1 
increased lung colonies from A375 melanoma in nude mice (8,14). 
Malignant melanoma constitutively produce IL-1 and other cytokines (18,21), some 
of which can induce adhesion molecules on EC in culture (6) In this study we 
investigated the adhesive behavior of A375 human melanoma after transfection with 
the human IL-1 gene We investigated the functional role of the protein product 
released by IL-1 transduced cells on the adhesive property of EC and the expression of 
inducible adhesion molecules on the EC surface The ability of IL-1- producing tumor 
cells to affect tumor-cell retention in the lung was investigated in nude mice given 
melanoma cells transduced with the IL-1 gene 
MATERIAL AND METHODS 
Animals 
Female NCr n u / n u (nude) mice were obtained from the National Cancer Institute 
Animal Program (Frederick, MD) and used when 6 to 8 weeks old 
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Cell culture 
The A375P human melanoma (3), the HT-29 human colon carcinoma (3), the 
A375P-IL-1 a/colony-1, -3, -6 transduced with the gene encoding for human IL-1, and 
the A375P-ß-gal transduced with a vector including the gene encoding for ß-
galactosidase (see below) were maintained in RPMI supplemented with 15% FCS 
(culture medium) Tumor cells were harvested by brief exposure to 0 25% trypsin -
0.02% EDTA, washed twice, and resuspended as indicated in the respective assays. 
Doubling time of A375P cells and its transfectants was calculated by seeding 1 χ IO4 
cells in 6-well flat-bottom tissue culture plates containing 2 ml of medium. Every 24 hr, 
cells from triplicate cultures were harvested with 0 25% trypsin - 0 02% TDTA, and the 
number of viable trypan-blue-exluding cells was determined using a hemacytometer 
chamber. Doubling time was calculated from the graph 
Conditioned medium (CM) of the A375P cells and their transfectants were obtained 
by seeding tumor cells in 75-cm2 culture flasks. At confluence, cell monolayers were 
washed three times with PBS and incubated for48hr with 7 5 ml of serum-free culture 
medium Supernatants were collected, centrifugcd al 2000 g and frozen at -80°C These 
supernatants were used for determination of secreted IL-1 by F.I.ISA and for EC 
activation 
EC were isolated from human umbilical vein as described (11) and maintained in 
Medium 199 supplemented with 10% FCS and 10% newborn calf serum, 5 μg/ml 
endothelial growth supplement, and 100 μg/ml of heparin 
Cytokines and antibodies 
Human recombinant IL-la (specific activity, 5 χ 10" units/mg) was obtained from 
Roche, and IL-lra was generously supplied by Synergen (Boulder, CO). MAbs to 
human VCAM-1 (CD106; clone 4B2), E-selectin (CD62E, clone 13D5) and 1CAM-1 (CD54, 
clone HC8/l)were from British Bio-technology (Oxford, UK) Anti-mouse secondary 
antibody conjugated with peroxidase was purchased from Sigma (St Louis, MO) Rat 
anti-mouse VCAM-1 (IgC2b) MAb (clone M/Kl 9) was obtained from ATCC 
(Rockville,MD) Cytokines and MAbs were stored in ahquots at-80°C until use For EC 
treatment, cytokines and MAbs were diluted in culture medium Treatment doses and 
schedules are indicated in "Results". 
Generation of LILlaSH retroviral vector and melanoma cell infection 
The engineered gene for mature human IL-1 flanked by HindlH and BamHl 
restriction enzymes and cloned within pUC18 was purchased from R&D systems 
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(Minneapolis, MN). The plasmid was linearized by Hindlll, blunted by T4 DNA 
polymerase and digested with BamHI. The resulting 500 bp IL-1 fragment was cloned 
into the Hpal/BamHI sites of LXSH retroviral vector to generate LILlaSH. The 
amphotropic PA317/LILlaSH producer cell line was generated by the transfection 
protocol starting from GP+E-86 ecotropic packaging cells according to procedures 
described by Colombo et al. (9). The producer cell line generated helper-free virus 
containing supernatant with a titer of 104 cfu/ml. Construction of the LBSN vector 
carrying the Eschericlna coli ß-gal cDNA and generation of the producer cell line have 
been described elsewhere (25). 
For target infection, 3 χ 10' A375P melanoma cells were treated for 4 hr with 
undiluted packaging cell supernatants in the presence of 8 mg/ml of polybrene. After 
medium change, cells were grown for 48 hr, then selected in hygromycin (LILlaSH 
infected cells) or neomycin (LBSN infected cells) Individual drug-resistant colonies 
were isolated, expanded into cell lines, and further analyzed 
RNA analysis 
Total cellular RNA was extracted by the guanidine-isothiocyanate technique, run in 
20-pg ahquots on 1.0% agarose-formaldohyde gels, transferred to nylon membranes by 
Northern blot, and hybridized to 107 dpm of DNA probe labeled to a specific activity of 
109 dpm/^gin the presence of 50% formamide and 10% dextran sulfate. Filters were 
washed at high stringency (0.2X SSC, 0 1% SDS at 55°C for 2 hr) and exposed to Kodak 
X-AR5 film for 16 to 48 hr at -70°C DNA probes were fragments of RT-PCR-derivcd IL-
1 and GAPDH cDNA, a SacII/PvuI fragment of LXSH containing the hygromycin 
resistance (Hygro) gene and a Hindlll/Smal fragment of LXSN containing the 
neomycin resistance (Neo) gene. 
Adhesion assay 
Tumor cell adhesion to EC was tested as described (8). Briefly, EC grown to confluent 
monolayers in 96-well plates were washed twice, then activated for 6 hr with IL-1 (2 
ng/ml), CM , IL-lra, or with combinations of CM and IL-lra (100 μΐ/well) at the 
concentrations indicated in the "Results". To test the involvement of adhesion 
molecules expressed on EC in tumor cell adhesion, activated EC were pre-incubated for 
30 min at 37°C with test medium alone or containing 20 μg/ml mAb anti-VCAM-1 or 
anti-E-selectin before the adhesion assay After incubation monolayers were washed 
twice and refilled with 50 μΐ RPMI containing 1% BSA (test medium) A375Pand HT-29 
tumor cells were radiolabeled with 5-12,I-iodo 2'deoxyuridine (Amersham, Aylesbury, 
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UK) as described (11) Aliquots (50 μΐ) of cell suspension (3 χ ICH cells) were added to 
each well and incubated at 37°C for 15 min (A375P cells) and 30 min (HT-29 cells) After 
incubation non-adherent cells were removed by careful aspiration and three washes 
with test medium Wells were incubated for 10 min with 100 μΐ of 0 1 M NaOH and the 
lysate was counted in a gamma counter 
Results are expressed as attached cells relative to total cells added Differences were 
analyzed by multiple comparisons using Dunnett's test 
Peroxidase-ELISA 
To establish the expression of adhesion molecules induced by tumor cells on EC, 
monolayers of EC in 96-well culture plates were washed and seeded with A375P-
colony-3 and colony-6 melanoma cells (1 5 χ 104 cells in 100 μΐ test medium) Control 
wells were incubated with test medium alone (no added tumor cells) or 100 μΐ of IL-1 
(2 ng/ml) After incubation at 37°C for 1,6 and 24 hr, wells were washed once with PBS 
+ 2 5% human serum (HS) Aliquots (50 μΐ) of anti-E-selectin or anti-VCAM-1 (10 
μg/ml) diluted in PBS + 2 5% HS were added Wells were incubated for 45 mm at room 
temperature, washed twice with PBS + 2 5% HS, then 100 μΐ of anti-mouse secondary 
antibody conjugated with peroxidase were added Wells were incubated for 45 min at 
room temperature and washed twice with PBS + 25 %HS 
E-selectin and VCAM-1 expression on EC was determined by addition of 100 μΐ of 
the soluble substrate 1,2-phenylenediamine in 0 1 M citrate buffer, pH 5 0 (Dako, 
Glostrup, Denmark), and H2O2 (final concentration 0 05%) The reaction was stopped 
by adding 100 μΐ of 1 M sulfuric acid to each well The resulting orange/brown color 
was determined by absorbance at 492 nm using a Titertek MS MCC/340 (ICN Flow, 
Rickmansworth, UK) E-selectin and VCAM-1 expression were expressed as 
absorbance 
Flow-cytometric analysis 
EC activated with IL-1 (2 ng/ml) or colony-6-СМ with or without the addition of IL-
lra (2 mg/ml), as described above, were harvested by brief exposure to 0 25% trypsin-
0 02% EDTA, washed twice and re-suspended in PBS with 2 5% HS The expression of 
adhesion proteins was determined by indirect immunofluorescence using a FACS-
STAR-Plus (Becton-Dickinson, Bedford, MA) (8) Briefly, after incubation with the 
appropriate primary antibody (1 50 dilution) in PBS with 2 5% HSA for 30 mm at 4°C, 
cells were washed and incubated with an affinity-purified FITC-labelled goat anti-
mouse immunoglobulin anti-serum for 30 min at 4°C (Tecno Genetics, Milan, Italy) 
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Results were expressed as percentage positive cells and mean channel fluorescence 
intensity. 
IL-la TRANSDUCED 
COLONIES: 
IL1-a 
hygro 
neo 
GAPDH 
ND 
3.9 
1.9 
4.1 
- 1.7 
1.4 
Figure 1. Northern-blot 
analysis of A375P melanoma 
cell line and of its IL-1 and ß -
gal retroviral-vector-
transduccd cells. 
The IL-1 message was detected 
only in colony-6 by the IL-1 
probe.The hygromycin probe 
detected two transcripts from 
LTR and SV40 promoters. 
Colonies 1 and 3 lacked the 
transcript from the LTR 
promoter detectable by the 
hygromycin probe, suggesting 
a possible rearrangement 
within the provirus. Both 
LTR- and SV40-promoter-
derived transcripts were 
detected by the neo-probe in ß -
gal-transduced cells. GAPDH 
was used for normalization. 
Organ distribution assay 
Cultures of colony-3 and colony-6 cells were rinsed twice and harvested as described 
above. Groups of nude mice (n=7) were pre-inoculated i.v. with colony-3 or colony-6 
cells (cold cells; 1 χ IO6 in 0.2 ml HBSS) or 0.1 μζ IL-1 or vehicle alone. After 6 hr two 
mice from each group were killed and lungs were immediately fixed in formalin and 
frozen in OCT before processing for histological and immunohistochemical analysis 
as described below. The remaining animals were injected i.v. with 5-[125I]-iodo 
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2'deoxyuridine prelabeled A375P cells ("hot" cells, 5 χ IO5 in 0 2 ml HBSS) (14) and 
killed 24 hr later, their lungs were collected and washed in three changes of 70% 
ethanol Radioactivity in the lungs was determined using a gamma counter (Gamma 
5000, Beekman, Palo Alto, CA) Results are expressed as the percentage of cell retention 
in the lung Differences were analyzed using the Mann-Whitney U test 
Histology and immunohistochemical analysis 
Lungs removed from nude mice 6 hr after the injection of colony-3 and colony-6 
cells, IL-1 or vehicle as described above, were immediately fixed in 10% phosphate-
buffered formalin or embedded in OCT (Miles, Elkhart, IN), then snap-frozen in liquid 
nitrogen For histological analysis, tissue samples were embedded in paraffin, 
sectioned at 4 μ, and stained with hematoxyhn-eosin For immunohistochemistry, 
acetone-fixed cryostat sections were treated with 0 3% H2O2 in methanol for quenching 
the endogenous peroxidase, air dried, and incubated with rat anti-mouse MAb VCAM-
1 at 4°C overnight After washing, they were overlaid with biotinylated rabbit-anti-rat 
Ig (Vector, Burhngame, CA) for 30 min at room temperature Unbound Ig were 
removed by washing, and the slides were incubated with ABC complex/AP (DAKO, 
Glostrup, Denmark) 
RESULTS 
IL-1 expression and secretion by IL-1 transduced A375P cells 
After transduction of the A375P melanoma cell line with LILlaSII retroviral vector, 
individual colonies selected for hygro-resistance were isolated and expanded for 
further analysis Northern blot analysis of A375P and of three transduced colonies 
showed message for IL-1 only in colony-6 (Fig 1) Accordingly only colony-6 secreted 
high levels of IL-1, as measured by ELISA in the CM (data not shown) None of these 
cell lines did not release detectable levels of IL-lß or TNF (data not shown) For our 
studies we therefore used the colony-6 releasing IL-1, and the colony-3 that did not 
produce detectable levels of IL-1 The A375P parental cell-line and transduced colonies 
had similar growth rates, with doubling times in vitto of 31, 29 and 38 hr for A375P, 
colony-6 and colony-3 tumor cells respectively, suggesting that IL-1 production by 
tumor cells does not change the growth rate and that the amount of IT-1 released in 
the CM does not depend on the growth rate 
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Figure 2. Adhesion of A375P melanoma to endothelial celh activated with CM from IL-1 -transduced 
сеііь 
A) Increased tumoi-cell adhesion to colony-6-СМ (13 dilution) activated EC EC were treated with 
medium alone (C), IL-1 (2 ng/nil) or CM from A375P, fi-gal, colony-3 and colony-6 
B) Dose-response pattern of tumoi-cell adhesion to EC activated with colony-6 CM EC were treated with 
medium alone (C), or various dilutions of colony-6-СМ 
C) Inhibition by IL-lra of tumoi-cell adhesion to EC activated by colony-6-СМ EC were treated with 
medium alone (C), colony-6-СМ alone or together with different conccntratioiib of IL-ha foi 6 Ins 
EC were tieated foi 6 hi at 37"C befoie the adhesion assay Adhesion of A375P cells was was evaluated 
after a further 30 nun Results show the attached cells as a pcuentage of total tells added Columns, mean 
oj tluee replicates and ι epi emulative of one of linee experiments, bai·,, SD 
* p<0 01, ** p<() 05 In Aand В compared to control treated EC (C), m С compared with EC treated with 
CM of colony-6 alone (0) 
Induction of EC adhesiveness by IL-1 transduced melanoma cells 
A375P and t ransduced colonies adhered equally to t issue cu l ture plastic, EC and 
extra-cellular matr ix (data not shown), suggesting thai ι he t ransduct ion of IL-1 does not 
modify the adhesive property of melanoma cells 
Adhesion of A 3 7 5 P m e l a n o m a cells was significantly increased on EC activated wi th 
colony-6-СМ for 6 hr (Fig 2A) Colony-6-СМ increased a d h e s i o n in a m a n n e r 
analogous to that of IL-1 which was used as a posit ive control for EC activation CM 
from A375P, colony-3 and ß-gal t ransduced cells did not change the adhesiveness of EC 
for A375P cells (Fig 2A) 
Colony-6-СМ increased EC adhesiveness in a dose-dependent fashion (Fig 2Б) A n 
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81-fold d i lu t ion completely abolished the capacity of colony-6-СМ to increase A375P 
adhes ion IL-lra a d d e d to colony-6-СМ dur ing EC activation inhibited the increased 
A375P adhesion (Fig 2C) and adhesion was completely blocked with > 80 n g / m l IL-lra 
Resting EC incubated for 6 hr with the same concentrat ions of IL-lra alone did n o t 
change their adhesivi ty for A375P cells (data not shown) Similar results were obtained 
with the second t u m o r line used in this study, HT29 h u m a n colon carcinoma, whose 
adhesion was increased to EC activated by colony-6-СМ (data not shown, Fig 3) 
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Figure 3 Adhesion of tumor 
LL'llb to cohmy-b-CM-activated 
EC in tlic presence of blocking 
antibodies 
A375P melanoma celh were 
added to EC aitwated with 
colony-b-CM pie-treated or 
not with anti-VCAM-1 HT-
29 colon-iarunonia cells were 
added to EC ai tivated with 
eolony-b-C M pre-tretited witli 
miti-E-\electm C, EC treated 
with contiol medium 
Results show the attaclied cells 
as a percentage of total cells 
added Columns, mean of 
tin ее i eplicales and 
icprcsentatme of one of three 
ί xpeiiimiit·*, ban, SD 
* p<0 01 compared to colony-
6-CM activated EC 
Induction of adhesion molecules on EC by IL-1 transduced melanoma cells 
To identify the adhes ion molecules induced by IL-1-transduced A37SP m e l a n o m a 
cells we s tudied the expression of E-selectin, VCAM-1 and intracellular- adhes ion 
molecule 1 (ICAM-1) on EC We used two methods In the first, the expression of 
adhes ion molecules on EC treated with CM from transduced colonies was analyzed by 
fluorescence-activated cell sort ing (FACS) Colony-6-СМ i n d u c e d the expression of 
VCAM-1 a n d E-selectin and increased the expression of ICAM-1 on EC (Table 1) 
Similar results were obtained by activating EC with IL-1, used as posit ive reference 
6 8 
The addition of IL-lra inhibited the IL-1 and colony-6-CM-induced expression of 
СЛМ-1 and E-sclectin and prevented increased expression of ICAM-1 on EC (Table 1) 
IL-lra alone did not influence the expression of adhesion molecules on EC (data not 
shown) As expected, colony-3-СМ did not induce the expression of CAM on EC (data 
not shown) 
Table 1. Induction of adhesion molecules on endothelial сеііь treated with 
conditioned medium fiom IL-1 -tiadduced A375Pmelanoma cells 
Endothehal-cell treatment0 
Antibody Control IL-1 IL-1 Colony-6-СМ Colony-6-СМ 
staining + IL-lra + IL-lra 
Anti-ICAM-1 88(421)b 98(613) 78(411) 99(550) 85(377) 
Anti-E-selectin 6(456) 92(552) 13(416) 95(510) 7(348) 
Anti-VCAM-1 4(413) 40(418) 1(571) 57(360) 2(373) 
a) EC were treated with nndium (control), IL 7 ahne (2 ng/ші) or togethei with IL Ira (2 mg/inl) or 
colony-6 CM alom (Ί 3 dilution) or together with IL-lra 
10 Results (determined by FACS апаіуыь) are the percentage oj positive cell* and the mean chanrn I of 
fluoie^cence intensity 
In the second method we co-cultured FC monolayers in pliysical contact with cells 
from colony-3 or colony-6 for 1, 6 and 24 hr and then measured the adhesion 
molecules on EC by peroxidase-ELISA Figure 4 shows that the co-culture of Г,С with 
colony-6 cells induced a time-dependent increase of VCAM-1 expression for 24 hr, 
while E-selectin induction reached a peak of expression at 6 hr, decreasing by 24 hr 
Cells from colony-3 did not increase either E-selectin or VCAM-1 expression (Fig 4) 
The kinetics of induction of CAM on EC bycolony-6-СМ was analogous to that by IL-1 
(data not shown) Similar results were obtained when the co-cultivation experiment 
was performed in transwells, thus with IL-1 secreting melanoma cells (upper 
compartment) not m direct contact with FC (lower compartmentXdata not shown) 
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Figure 4. Tune course of E-selectm and VCAM-1 expression by EC co-cultured with IL-1-transduced 
melanoma cells. 
Colony-3 (*•*) and colony-6 cells (o·) were incubated for 1, 6 and 24 kr with EC. E-selcctm (on.) and 
VCAM-1 (*A) expression are expressed as absorbanceai 492 nm Data are mean of three replicates and 
lepresentatwe of one experiment out of two done. Positive contiols, tieated with IL-1, showed іпсіспыч) 
expression of E-selectm (abs 0 314; 0 790, 0 443 at 1, 6 and 24 hr respectively) and VCAM-1 (abs 
0 315; 0 505; 0.654 at 1, 6 and 24 hr respectively) (data not shown m i igure) 
E-seìectin and VCAM-l induced by IL-1 transduced melanoma cells mediate tumor cell 
adhesion to EC 
To investigate the role of these molecules in the adhesion of tumor cells on EC, we 
used blocking MAbs against CAM induced on EC by IL-1 secreting melanoma The 
increase in adhesion of A375P melanoma cells to colony-6-СМ activated EC was 
inhibited by antibodies to VCAM-1 (Fig.3). E-selectin antibodies did not affect their 
adhesion (data not shown). However, the increase in adhesion of HT-29 colon 
carcinoma cells to EC was completely blocked by antibodies to E-selectin (Fig3), while 
VCAM-1 antibodies had no such effect (data not shown) 
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Increased retention of A375P cells in the lungs of mice ¡ire-treated with IL-1 transduced 
melanoma cells 
To investigale the role of IL-1 producing melanoma cells in the organ distr ibution of 
melanoma cells in ν ι vo, we studied the ability of radiolabeled Λ375Ρ cells ("hot" cells) 
to arrest in the lungs of n u d e mice pre-treated 6 hr earlier with IL-1 t ransduced cells 
("cold" cells). Significantly more " h o t " cells were retained in the lungs of mice p r i m e d 
6 hr earlier with colony-6 cells than in the lungs of mice pr imed with colony-3 cells 
(Fig 5) Colony-6 cells increased tumor cell retention in the lung, similarly to IL-1 used 
as reference (Fig 5; Ref.14). Cell-associated radioactivity in the liver did not differ 
among groups (data not shown). " H o t " colony-3 or colony-6 cells per se did not s h o w 
remarkable differences in their ability to arrest in the lung 6 hr after injection in 
normal, mice not pre-treated (data not shown) 
Colony-3 Colony-6 Vehicle 
Figure 5. Lung distribution of 
Λ375Ρ cells 
Gwups of nuce (N=5) were pre­
sented by ι ν injection of 0 1 μ% 
IL-Ί, vehicle, colony-3 or colony-
6 сеііь О л 10ь cold cells) in 0.2 
nil HBSS Ajtei 6 hr mice weie 
injected with 5-12:,l-iodo 
2''deoxyui idme-labeled A375P 
cells (5 χ W5 "hot" cells). 
Peicenlage of the originally "hot" 
injected A375Pcells remaining m 
the lung was measured after 24 
hi Results aie the mean ± SD of 
'jive lungs per group. 
p<0 07 and " p<0 05 
compili ed with vehicle-pre-trcated 
annuals 
Expression of VCAM-1 on lung vascular endothelium of mice injected with IL-1 
transduced melanoma cells 
Having found that colony-6 cells, like IL-1, increase A375Pcell retention in the lungs 
of n u d e mice, we investigated the expression of the adhesion molecules responsible 
for melanoma-cel l v a s c u l a r - e n d o t h e h u m interact ions (13) I m m u n o h i s t o c h e m i c a l 
staining with anti-VCAM-1 showed that VCAM-1 was induced on lung vascular EC of 
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mice given IL-1, used as reference, and the expression of VCAM-1 was higher on lung 
vascular EC of animals injected with colony-6 cells (rig 6) The EC of animals injected 
with colony-3 cells was negative (Fig 6), and not different from vehicle treated mice 
(data not shown) 
DISCUSSION 
The role of the inflammatory cytokine IL-1 in the metastatic cascade is likely to be 
complex IL-1 increases metastasis in different experimental models (2,3,14), most 
probably as a consequence of increased tumor cell adhesion to cytokine-activated 
vascular endothelial cells The production of cytokines, including IL-1, by melanoma 
cells has been described (18,21), but their role in tumor progression and metastasis is 
not well understood In this study we found thai, after IL-1 gene transfcclion, IL-1 
producing melanoma cells activated vascular endothelial cells that became prone to 
tumor-cell adhesion 
The role of tumor-derived IL-1 in the tumor-EC interaction has been described for 
melanoma and pancreatic carcinoma lines that constitutively synthesize IL-1 (6,17) 
Burrows et al (6) found that IL-1 present in melanoma-conditioned medium could 
induce the expression of adhesion molecules on EC and increase the adhesion of 
tumor cells to EC Melanomas produce many other cytokines (e g , TNF«) (21) that may 
affect EC activation, so the role of IL-1 produced by them is unclear By using 
melanoma cell colonies transduced with the gene for IL-1, we have found direct 
evidence of the role of tumor-produced IL-1 in tumor-EC interaction In our study, 
only colony-6 cells, which secrete IL-1 in the cultured supernatants, activated EC 
adhesion, whereas colony-3, which does not release IL-1, had no effect on EC 
adhesiveness 
FI ISA of the cultured medium and Northern-blotting analysis for the presence of 
IL-1 in colony-6 suggested that this cytokine was responsible for EC activation Colony-
6-CM appeared very potent in stimulating the EC (a 27 fold dilution of CM maintained 
the capability to activate EC)(Fig 2) Although additional cytokines/factors produced by 
colony-6 cells, other than IL-1 and TNF, could synergistically enhance expression of 
adhesion molecules on EC, the fact that IL-lra, while not neutralizing the activity of 
other cytokines (7,16), blocked the increase in expression of adhesion molecules on EC 
and the increased adhesion of tumor cells induced byCM from colony-6, indicates that 
tumor cell-produced IL-1 specifically plays a role in this increase 
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Figure 6. Histology and immunoperoxidase. 
Histological (capital letters) and immunohistochcmical (small letters) analysis of lung sections from nude 
mice which had beeni.v. injected 6 hr earlier with 1 χ ΊΟ6 colony-6 cells (Α,α), Ì χ IO6 colony-3 cells (B,b) 
or 0.1 ßg IL-1 (C,c). Colony-6 (A) and colony-3 (B) tumor cells (arrowheads) obstruct the lumen of small 
blood vessels. Immunoper oxidase staining with MAb to VCAM-1 shows a marked posiHvily of lung 
vascular endothelium of mice receiving colony-6 cells (a) and IL-1 (c). The lung vascular endothelium of 
mice receiving colony-3 cells was negative (b). Scale bar, 30 μηι. 
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A375P melanoma cells transduced with IL-1 did not become more adhesive to 
resting EC or extracellular matrix components (data not shown), but the co-cultivation 
of IL-1-producing melanoma cells (colony-6) on the EC monolayer increased the 
expression of adhesion molecules, including VCAM-1 and E-selectin, which in turn 
mediated the enhanced adhesion of tumor cells (Figs 3,4) The induction of adhesion 
molecules on EC by IL-1 transduced colony-6 is time-dependent, with kinetics of 
induction comparable with that described for recombinant IL-1 (5) In these 
circumstances, colony-6 cells or their culture supernatants had to be incubated 4 to 6 hr 
with EC to increase the attachment of tumor cells to EC Accordingly, IL-1-transduced 
cells injected ι ν do not increase their arrest in the lung of nude mice However, when 
these mice were primed for 6 hr with tumor cells releasing IL-1 their retention 
increased, confirming the time dependence of induction/activation of vascular 
adhesiveness We have shown earlier that after ι ν injection A375P melanoma cells 
rapidly localized in the lungs of nude mice but remained at higher level in the lungs 
of mice receiving IL-1 (14) 
These results are somewhat in contrast with the findings of Burrows ct al, (6), who 
showed higher adhesivity to EC of melanoma cells secreting IL-1 than that of non-
secreting cells However, that study compared tumor lines of different origin, and 
mechanisms other than IL-1 secretion might be responsible for their adhesion 
Moreover, the expression of ICAM-1 was increased on IL-1-secreting tumor cells (6), 
whereas in our study transduced colonies showed no difference in tumor-cell-surface 
adhesion molecules such as ICAM-1 or ßl integrins («4 and a5) (data not shown) 
which might be responsible for melanoma-cell adhesiveness (1,13,15) 
The expression of adhesion molecules on EC was increased after incubation with 
colony-6-СМ or co-cultivation with colony-6 cells The expression of VCAM-1 and E-
selectin on EC was associated with increased tumor cell adhesion, since antibodies 
against these molecules blocked the increase in adhesion of A375P melanoma and HT-
29 colon carcinoma cells respectively Our findings confirm that these mechanisms 
play a role in cytokine-enhanced tumor EC adhesion, and agree with our earlier 
findings that A375P melanoma and HT-29 colon-carcinoma cells adhere to IL-1-
activated EC preferentially through VCAM-1 (integrin-mediated pathway) and E-
selectin (selectin-mediated pathway) respectively (12,13) 
These results have implications for the role of IL-1 in tumor biology IL-1 produced 
by the host in response to inflammatory stimuli can increase experimental metastases 
(8) However, even in the absence of inflammation, vascular EC can be activated by IL-1 
released by the tumor, either directly or through the induction of other cytokines 
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Blood-borne metastasis is caused by the circulation of tumor cells alone, or in clusters, 
which then arrest in the small vessels of secondary organs (10). We found increased 
VCAM-1 expression on vascular endothelium of lungs of mice injected with IL-1-
secreting tumor cells, which in turn might explain the increased retention of 
radiolabeled A375P melanoma cells in the lungs of nude mice primed with colony-6 
cells (Fig.5) 
In conclusion, the present work provides evidence that local concentrations of 
tumor-cell-derived IL-1 in small vessels induce EC activation, further facilitating the 
subsequent arrest of other tumor cells. 
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associated with tumor growth in nude mice 
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We have studied the cytokine regulation of cell surface and soluble intercellular 
adhesion molecule 1 (ICAM-1) expression on the human melanoma cell line A375M. 
Unstimulated cells express ICAM-1 on their cell surface but do not secrete significant 
levels of soluble ICAM-1. Interleukin 1, interleukin 6, tumor necrosis factor, and γ-
Interferon all increased cell surface expression of ICAM-1. Tumor necrosis factor, 
interleukin 1, and γ-Interferon also caused the release of soluble ICAM-1. The serum of 
melanoma patients has been reported to contain elevated levels of soluble ICAM-1; 
however, the source of this ICAM-1 is unclear. The serum from nude mice bearing s.c. 
human melanoma tumors was found to contain soluble ICAM-1. ICAM-1 levels 
showed a positive correlation wih tumor weight. The release of ICAM-1 from 
melanoma tumors, in response to host-derived cytokines, may have relevance to 
immune recognition of the tumor. 
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INTRODUCTION 
Cell adhesion molecules which mediate homotypic and heterotypic cell interactions 
are thought to have several important roles in tumor progression They can control 
tumor cell dissociation from the primary tumor and interactions with host cells 
during dissemination, adhesion and invasion of metastatic sites ICAM-1 was 
originally shown to mediate homotypic lymphocyte aggregation and adhesion to 
cultured endothelial cells (1,2) ICAM-1 has susequently been demonstrated in a 
number of different cell lineages Soluble forms of ICAM-1 have been described in 
normal human serum (3), and elevated levels have been shown in inflammatory 
diseases (4,5) ICAM-1 can be found on cells of the melanocyte lineage, preferentially 
on cells undergoing malignant transformation, its expression correlated with the 
thickness of the lesion and was predominantly associated with metastases (6,7) A 
recent report has described soluble ICAM-1 in the serum of patients with malignant 
melanoma (8), although the source of soluble ICAM-1, from either the host or the 
tumor, was unclear 
The nude mouse model is a powerful system with which to study human tumors 
in vivo Human xenografts have been reported to maintain histological, molecular, 
and biochemical characteristics of the tumor of origin (Reviewed in ref 9) In this 
study, we have investigated the production of soluble ICAM-1 from cytokine-
stimulated human melanoma cells in culture and have measured levels of soluble 
ICAM-1 in the serum of nude mice bearing tumors derived from the same cells 
MATERIALS AND METHODS 
Animals 
NCr nu/пи nude mice, 6 to 8 weeks old, were obtained from the National Cancer 
Institute Animal program, Frederick, MD Mice were maintained throughout the 
experiments under specific-pathogen-free conditions and in accordance with 
institutional guidelines 
Tumor lines 
The human cell lines A375M melanoma, HT29 colon carcinoma, and the SN12-K1 
renal carcinoma were routinely cultured as previously described (10) Tumor cells were 
harvested by exposure to 0 25% trypsin-0 02 EDTA solution, washed twice, and 
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resuspended in test medium Tumor cells (2xl05) were seeded in 6-well culture plates 
in 2 ml of Dulbecco's modified minimal essential medium containing 10% fetal call 
serum After 24 h, monolayers were washed and 2 ml 10% fetal calf serum-Dulbecco s 
modified minimal essential medium with or without cytokines (IL-1, 500 units/ml 
TNF, 500 units/ml, IFNy, 500 units/ml, IL-6, 200 units/ml) were added After 72 h 
supernatants from treated and untreated wells were collected, centnfuged and frozen 
at -80°C The cell monolayers were washed twice, subjected to two rounds of 
freeze/thawing, mechanically removed, soncated to yield a cell lysate, and frozen at 
80°C Tumor cells were also harvested from separate wells and processed for flow 
cytometric analysis 
Flow cytometric analysis 
The expression of ICAM-1 was determined by indirect immunofluorescence using η 
FACScan analyzer (Becton Dickinson) Briefly, after incubation vwth the appropriate 
primary antibody, cells were washed and incubated with an affinity-purified 
fluorescein isothiocyanate-labeled goat anti-mouse immunoglobulin antiserum 
(Tecno Genetics, Italy) Results were expressed as percentage positive cells (after 
background subtraction) and mean channel fluorescence intensity 
Reagents and antibodies 
The following cytokines were a gift from the indicated sources rIL-1 (specilic 
activity, 3 xlO8 units/mg) from Sclavo,Italy, rTNF (specific activity 8 1 χ10ή units/mg) 
from Basf-Knoll, West Germany rlFNy from NIBSC, United Kingdom, and rll 6 
(specific activity lxlO6 units/mg) from British Biotechnology Products, United 
Kingdom Antibodies specific for human ICAM-1 (BBIG-I1 and 13B1G-I2) v\ ere obtained 
from British Biotechnology Products, and those to LFA 1 from J Ritz, Dana Fabei 
Cancer Institute, Boston, USA 
ELISA 
Microtiter CLISA plates (Nunc Immunopiates, I lfe Technologies, Paisley, Scotland) 
were coated with the capture antibody BBIG-I1 specific for human ICAM-1 Antibod) 
was diluted in 0 1 M bicarbonate buffer, pH 8 9 to a final concentration of 10 Mg/ml and 
50μ1 added to each well Plates were incubated at 40°C overnight followed by washing 
tVMce with PBS-T Blocking was achieved byadding 100μ1 per well of PBS-T containing 
1% casein and incubating at room temperature for 2 h Following a further three wash 
cycles, the ICAM-1 standard and samples were added to the plate (50 μΐ per well) and 
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left to incubate for 2 h at room temperature After three washings with PBS-T the 
bound soluble ICAM-1 was detected using a human ICAM-1-specific biotin labelled 
antibody BBIG-I2 Antibodies were diluted in PBS-T to a final concentration of 5 
μg/ml/ and 50 μΐ/well added for 1 h at room temperature The plates were washed 
another three times and 50 μΐ of a 1 1000 dilution of streptavidin horseradish 
peroxidase (Amersham International Amersham, United Kingdom) was added to each 
well After incubation for 30 min and three final washes with PBS-T, the plates were 
developed using 50 μΐ/well of tetramethylbcnzidine (Universal Biologicals, Kingston 
upon-Thames, United Kingdom) The reaction was stopped after 30 min by the 
addition of 50 μΐ 1 0 M HCl/well and read using a Titertek MS-2 reader (ICN Flow 
Rickmansworth, United Kingdom) at 450 nm Soluble adhesmb were quantified in 
arbitrary units/ml against an affinity-purified standard preparation of recombinant 
ICAM-1 expressed in СПО cells and solubihsed by detergent extraction 
Tumor Gioiuth 
Tumor cell suspensions containing 2x106 cells in 0 2 ml 0 9% NaCl were injected s с 
in the flank of nude mice Tumor growth was followed by measuring tumor diameters 
with calipers and the tumor weight was calculated as length χ width2-^ 2 Four weeks 
(about 500 mg tumor weight) and 8 weeks (>1200mg) after tumor injection, blood was 
obtained by intracardiac puncture Serum was obtained by centrifugaron, frozen, and 
maintained at -80°C before analysis 
RESULTS 
1СЛМ-1 expicsston aun secretion by Λ375Μ cells 
As shown in Table 1, A375M cells express a basal level of ICAM-1, as measured by 
fluorescence-activated cell sorter analysis and by CLISA of ICAM-1 released from the 
cells by free/e/thawing (cell-associated) ICAM-1 expression was moderately increased 
by IL-1, IFNy or IL-6 stimulation but was significantly increased after treatment with 
TNF Soluble ICAM-1 was not detectable in the supernatant of unstimulated cells, 
although cell-associated ICAM-1 was present A375M cells stimulated with IL-1, IFNy 
and TNF released soluble ICAM-1 into the culture supernatant IL-6 stimulation had 
no significant effect on soluble ICAM-1 release 
HT29 colon carcinoma cells could be stimulated by IFNY to express high levels of 
cell-associated ICAM-1 but secreted only low levels of soluble ICAM-1 SN12-K1 renal 
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carcinoma cells showed marginal increases in cell associated ICAM-1 following I F N Y 
stimulation, and no soluble ICAM-1 production 
Table 1. ICAM-1 expression and secretion by tumor cells in culture. 
Mean Fluorescence cell associated Soluble 
Tumor cell Stimulus (% of positive cells) (units/ml) (units/ml) 
Melanoma A375M 
Colon carcinoma HT-29 
Renal carcinoma SN12-K1 
Medium 
IL-1 
TNF 
IFNY 
IL-6 
Medium 
IFNv 
Medium 
IFNY 
71 (99) 
124(100) 
296(100) 
114(100) 
106(100) 
45 (25) 
368(100) 
28 (32) 
34 (73) 
1 1 
60 
14 8 
46 
28 
05 
20 0 
02 
04 
0.5 
9.6 
19 6 
40 
07 
ND^ 
06 
ND 
ND 
Tumor cells were exposed to cytokines for 72 h prior to flow cytometry for cell surface ICAM-1 expression 
or measurement of soluble (secreted) and cell-associated (solibilized) ICAM-1 levels Results aro 
representative of three independent experiments 
a) ND, below limit of detection 
Serum ICAM-1 levels in nude mice bearing A375M melanoma 
Having found that A375M cells can secrete ICAM-1, we investigated ICAM-1 release 
into the se rum of an imals bearing a growing tumor (Fig 1). Eight of the ten mice 
bear ing the A375M s.c. t umor showed significant level of circulating ICAM-1 in their 
se rum (ranging from 6 to 31 u n i s t / m l ) ; only two mice bear ing tumor did not show 
detectable levels of ICAM-1 in serum. Six mice with no detectable t u m o u r had n o 
detectable ICAM-1 in their serum. Some correlation with the se rum level of ICAM-1 
and the t umor size was observed, the highest levels of ICAM-1 being found in the 
serum of mice with the largest tumors. 
Sera collected from n u d e mice bearing SN12-K1 renal carcinoma (mean weight, 2 3 
g), HT-29 colon carc inoma (mean weight , 2.8 g), or the m u r i n e m e l a n o m a 131o 
contained no soluble ICAM-1 (data not shown) 
84 
Figure 1. Serum levels of 
ICAM-1 in tumor-bearing 
nude mice Each point 
represents an individual 
animal, ο,tumor-free nude 
mice Shadded area includes 
serum level below limit of 
detection. 
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DISCUSSION 
Measurement of ICAM-1 expression has been proposed for the diagnosis and 
prognosis of malignant melanomas We have shown that cultured human melanoma 
cells express ICAM-1 on their cell surface and have also shown that they can release a 
soluble form of ICAM-1. Some unstimulated melanoma cells express ICAM-1 
constituitively, possibly due to autocrine stimulation byIL-1 (11), but can be stimulated 
by cytokines to increase expression γ-Interferon treatment of the HT29 colon cells 
resulted in a massive up-regulation of cell surface/cell associated ICAM-1, to levels 
greater than those seen on melanoma stimulated with TNF Despite this, only 0 6 
units/ml of soluble ICAM-1 were detected in the cell supernatant, compared to 19 6 
units/ml in the melanoma supernatants. This suggests that there is a specific 
mcchamism of release from A375M cells 
A recent report has demonstrated elevated levels of soluble ICAM-1 in the blood of 
patients with melanoma, although the source of the ICAM-1 was not identified 
ICAM-1 could be produced either by the tumor or by the host cells in response to the 
tumor We have shown that melanoma cells in culture can be stimulated by some 
inflammatory cytokines to release a soluble form of ICAM-1 and that nude mice 
carrying transplanted melanoma tumors have ICAM-1 in their blood 
As our ELISA does not detect murine ICAM-1, the demonstration of soluble ICAM-
cn 
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1 in the serum of the nude mice bearing melanoma tumors confirms that the human 
tumor is the source of the ICAM-1 No ICAM-1 was detected in the serum of mice 
without tumors or those bearing the murine the B16 melanoma Nude mice bearing 
HT29 human colon carcinoma or SN12-K1 renal carcinoma showed no detectable 
ICAM-1 in their sera 
Locally produced cytokines may be important for expression and secretion oflCAM 
1 from tumor cells In the nude mice, endogenous murine IL-1 and TNF, which acl 
across species, could stimulate the human tumors Since murine IFNy is inactive on 
human cells it could not induce ICAM-1 expression (12) In the melanoma-bearing 
animals sufficient cytokine stimulation would seem to be available to cause the change 
from the nonsecreting phenotype, seen in cultured cells, to the ICAM-1 secreting 
phenotype observed in vwo 
ICAM-1 is a counter-receptor for leucocyte ß2 integrins such as LFA-1, and plays an 
important role in the interaction of target cells with the immune system Expression ol 
ICAM-1 by tumor cells may therefore enhance immune recognition and be associated 
with a favorable prognosis (13) Down-regulation of ICAM-1 by Burkitts lymphomas 
clones has been associated with their capacity to escape immune surveilance (14) It is, 
however, possible that ICAM-1 expression may help tumors escape the immune 
response Interaction of the tumor with leukocytes could result in release of toxic 
cytokines or mediators These may cause tissue damage and allow dissociation of the 
primary tumor, promoting tumor migration and extravasation Circulating tumor 
cell/leukocyte aggregates could also be prone to arrest in capillary beds, thus enhancing 
metastasis 
The demonstration of soluble ICAM-1 release by tumor cells may pro\ ide 
additional escape mechanisms Shedding of ICAM-1 by melanoma cells in response to 
cytokines could leave insufficient cell surface ICAM-1 to allow effective recognition by 
cytotoxic lymphocytes It is also possible that high local concentrations of soluble 
ICAM-1 could act to block ß2 ïntegrin sites on the leukocytes and therefore block 
immune recognition Evidence to support this has recently come from Becker ci nl 
(15) who have shown that soluble ICAM-1 from melanoma cells can block natural 
killer or lymphokine activated killer cell-mediated cytotoxicity Whatever the 
functional role of cell surface or soluble ICAM-1 in tumour progression, the detection 
of soluble ICAM-1 in serum represents a potential prognostic marker for malignant 
melanoma The diagnostic potential may, however, be limited, inasmuch as serum 
ICAM-1 can be elevated in a wide range of inflammatory diseases (5) In this respect 
the nude mouse/human melanoma model system represents a powerful tool tor 
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further studies on the role of ICAM-1 in tumor progression. 
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Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a 
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The synthetic matrix metalloproteinase inhibitor, batimastat, was tested for its 
ability to inhibit the growth and metastatic spread of the B16-BL6 murine melanoma 
in syngeneic C57BL/6N mice. Intraperitoneal administration of batimastat resulted in 
a significant inhibition in the number of lung colonies produced by B16-BL6 cells 
injected i.v. The effectof batimastat on spontaneous metastases was examined in mice 
inoculated in the hind footpad with B16-BL6 melanoma. The primary tumor was 
removed surgically after 26-28 days. Batimastat was administered twice a day from day 
14 to day 28 (pre-surgery) or from day 26 to day 44 (post-surgery). With both protocols, 
the median number of lung metastases was not significantly affected, but there was a 
significant reduction in the weight of the metastases. Finally, the effectof batimastat 
was examined on the s.c. growth of B16-BL6 melanoma. Batimastat administered daily, 
starting at day of tumor transplantation, resulted in a significant growth delay, whereas 
treatment starting at advanced stage tumor only reduced tumor growth marginally. 
Our results indicate that a matrix metalloproteinase inhibitor can not only prevent the 
colonisation of secondary organs by B16-BL6 cells but also limit the growth of solid 
tumors. 
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INTRODUCTION 
Proteolytic degradation of the extracellular matrix (ECM) is believed to be a key 
element in cancer invasion and metastasis, and several classes of enzyme have been 
implicated in this process (10) Much attention has focused on matrix 
metalloproteinases (15,24) These enzymes are secreted in latent form by both normal 
and tumor cells andare activated bv removal of a conserved amino-terminal domain 
(22) Correlative studies using human tissue from clinical material have linked 
expression and activation of members of the matrix metalloprotemase family to tumor 
progression and spread (4,7) Functional studies with the native inhibitors of these 
enzymes, TIMP-1 and TIMP 2 (tissue inhibitors of metalloproteinases), have shown 
that matrix metalloproteinases facilitate tumor invasion in vitto (1,8) and metastatic 
spread in vivo (2,21) 
What has not been clear from these studies is the extent to which inhibitors of 
matrix metalloproteinases might restrict tumor growth There are 2 principal ways in 
which this might occur, (ι) by direct inhibition of ECM breakdown preventing invasive 
growth by tumor cells, or (n) b) inhibition of tumor neovasculansation leading to 
tumor necrosis Inhibition of ECM breakdown by matrix metalloprotemase inhibitors 
has been demonstrated in viti о (17), but has been difficult to quantify in vivo Other 
studies have shown thai a form of TIMP derived from cartilage could inhibit tumor-
induced neovasculansation of rabbit cornea, presumably by blocking the breakdown of 
I CM that precedes new capillary growth (18) 
We investigated here the eflect of a synthetic metalloprotemase inhibitor, 
batimnslat, on primary tumor grow th, metastatic spread, and secondary tumor growth 
in vivo For this purpose, we used the B16-BL6 mouse melanoma, an aggressive 
variant of the B16 cell line, which can be studied as both a lung colonisation and a 
spontaneous metastasis model (23) The B16 melanoma model was particularly suited 
for our study since previous work had shown that both TIMP-I (21) and a synthetic 
matrix metalloprotemase inhibitor, SC44463, (20) could inhibit lung colonisation 
(experimental metastasis) bv these cells The principal degradative enzyme secreted by 
BI6-BL6 cells appears to be the 72-kDa type IV collagenase (16) Subcutaneous injection 
of B16-BL6 cells gi\es rise to rapidlv growing in\asne tumors with the potential to 
metastasize The principal target organ for metastasis is the lung The objective of our 
study was to define the points at which inhibitors of matrix metalloproteinases might 
inhibit the process of tumor metastasis and thereby identify conditions in which such 
inhibitors may be expected to yield clinical benefits 
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MATERIAL AND METHODS 
Mice 
Five- to 6 week old female C57BL/6N mice were obtained from Charles River 
(Calco, Italy) Animals were age- and weight-matched within each experiment 
Tumor cells 
The B16-BL6 murine melanoma is a variant, highly metastatic to the lung, of 
syngeneic C57BL/6N mice (23), selected from the parent B16 cell line (14) Tumor cells 
were maintained on plastic in Eagle's minimum essential medium supplemented 
with 2mM L-glutamine, lmM sodium pyruvate and 10% FBS Tumor cells were 
harvested in growth phase by brief exposure to 0 25% trypsin - 0 02% EDTA, washed 
twice and resuspended in Ca2+ and Mg2+-free Hanks' balanced salt solution (HBSS) at 
the concentration indicated for the respective assays 
Batimastat 
Ba timas tat ([BB-94, 4-(N-hydroxyamino)-2R-isobutyl-3S-(thienylthiomethyl)-
succinyl]-L-phenylalanine-N-methylamide, mw = 478) was provided by British Bio­
technology (Oxford, UK) IC5()S were determined for Batimastat in vitro against the 
following metalloproteinases interstitial collagenase, 3nM, stromelysin, 20nM, 72kDa 
type IV collagenase, 4nM, 92-kDa type IV collagenase, 4nM, and pump, 6nM 
Batimastat was suspended bysonication at3 0mg/ml in PBS containing 0 01% Tween-
80 (pH 7 2) This preparation was injected i p into mice at the concentrations and 
schedules indicated in the respective experiments Control animals received the same 
volume of vehicle 
Pharmacokinetic analysis 
The concentration of batimastat in the blood of treated mice was determined by an 
ex-vivo bioassay Briefly, 0 5 ml of blood was taken by cardiac puncture at appropriate 
times and placed in a polypropylene tube containing 3 ml of methanol The 
precipitated proteins were separated bycentnfugation, and 2 5 ml portions of methanol 
extract dried under vacuum 
The extracted batimastat was resolubilized in 200 μΐ DMSO and added to tubes 
containing radiolabeled type I collagenase The concentration of inhibitor in the blood 
extracts was determined by compansion with the degree of inhibition of collagenase in 
parallel incubations that contained known concentrations ot batimastat Separate 
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experiments in which batimastat was added directly to whole blood revealed that the 
extraction efficiency of the methanol process was approximately 50% The values 
presented in the "Results" are not corrected for this factor 
Prolifeiatton assay 
B16-BL6 cells were seeded into 24-well culture plates at a concentration of IxlO4 / m l 
/ well, in Dulbecco's modified medium containing 5% (v/v) FBS Batimastat was 
dissolved in absolute ethanol at a concentration of 3mM This stock was further 
diluted in absolute ethanol to give a range of concentrations, as indicated Batimastat 
was added to the wells 4 hr post seeding in a 2-μ1 volume Each concentration of 
batimastat was tested in duplicate Absolute ethanol (2 μΐ) was added to 2 wells as a 
vehicle control, and 2 wells were left untreated as a cell control The plates were 
incubated in a humidified C0 2 incubator at 37°C After 22 hr, 1 μ Ο PH]-thymidine was 
added to each well for 2 hr Cells were washed twice and 1 ml of ice-cold 5% (w/v) TCA 
was added to each well Plates were left on ice for 30 min, washed 3x with 5% TCA and 
2x with absolute ethanol After drying, the TCA-insoluble material was solubilized in 
300 μΐ / well 0 1% trypsin for 1 hr at 37°C, followed by 300 μΐ / well of 0 1% SDS A 500-
μΐ aliquot was removed for measuring radioactivity using a scintillation counter 
Subcutaneous tuiuoi growth assay 
Mice were injected s с in the dorsal scapular region with 2 χ Ю-3 tumor cells in 0 2 
ml HBSS Mice were randomized in 3 experimental groups receiving vehicle or 
batimastat treatments daily ι ρ until the end of the experiment Batimastat treatments 
(30 mg/kg) started respectively on the day of tumor implantation and when tumors 
reached a palpable size (3 5 mm in diameter) Tumor growth was measured twice a 
week with a caliper and tumor weight estimated by the formula length χ width2/2(13) 
Tumor weights were plotted against days after inoculation and tumor doubling time 
was calculated from the resulting graph Four additional tumors per group were 
excised at days 11 and 15 and processed for histological and immunocytochemistry 
analysis as described below 
Spontaneous metabtnsis assay 
Mice were injected in the hind foot-pad (f ρ ) v\ith 4 \ 10^  tumor cells in 0 05 ml 
HBSS The growth of the primary tumor was monitored bv caliper measurement, and 
when tumors reached approximately 250 mg (range 110-530 mg), mice were 
anesthetized and their tumors removed surgically proximal to the popliteal lymph 
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nodes Batimastat was given at a concentration of 15 mg/kgi.p twice a day according to 
2 different experimental protocols In the first, mice received batimastat from day 14 
(palpable tumor) until the day of surgery (pre-surgery treatment); in the second group 
mice received balimastat from the day of surgery until termination of the experiment 
(post-surgery treatment) Control groups received vehicle alone. Since treatment with 
batimastat delayed growth of the primary tumors, the tumors were removed from this 
treated group 2 days later than in the control group when they were of equivalent size 
(Table I) Mice were killed 18 days post-excision of the primary tumor, and lungs were 
fixed in Bouin's solution. The number and size of metastases in the lungs were 
determined with a dissection microscope and metastasis weight per lung calculated 
from the size of the metastases, as previously described (12) 
Table 1. Effect of batimastat on spontaneous metastasis in min Ικαπηχ Bib ULb imitinomi! 
Median tumor Number of mice Median number Median weight (g) 
Treatment 1 Schedule weight (g) at surgery with lung of metastases of metastases 
(range) metastases (range) (range) 
Vehicle 
Batimastat 
Vehicle 
Batimastat 
Pre-surgery 
Post-surgery 
0 23(0 16-0 39) 
0 27(0 17-0 39) 
0 26(0 11-0 53) 
0 28(0 11-0 51) 
9/9 
9/9 
11/12-
9/132 
7(1-57) 
6(1-20) 
7(0-57) 
2 (0-26) 
29.8 (1 0-209 8) 
71 (0 5-73 3P 
35 1 (1 0-224 0) 
8 4 ( 1 0-57 0)1 
Tumor ceils 4 χ 105 were injected into f μ and autopsies performed 3 week·* after the surgical excision of the primary tumor 
Results are representative of two different experiments 
1) Mice were treated twite a day ι ρ with batimastat tl5mt>fk$ per inoculum) irom day 14 to 2S (pre surgi ry) anil from dai/ 26 to 44 (post· 
surgery) 
2) Absence of metastasis confirmed by histological analysis 
3) p<0 02 compared to control 
4) p<005 compared to control 
Lung colonization assay 
Mice were injected with 5 χ 10"1 tumor cells in 0 2 ml 11BSS m the lateral tail vein 
Batimastat at a concentration of 30 mg/kg, or vehicle, was given ι ρ as indicated Mice 
were killed 21 days later, the lungs fixed in Bouin's solution, and lung colonies 
counted with a dissection microscope 
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Organ distribution assay 
Cultures of B16-BL6 cells were prelabeled with 5-[125I]-Iodo-2'deoxyuridine 
(Amersham, Aylesbury, UK) at 0.3 mCi/ml for 24hr (11) The cell monolayer was 
rinsed twice and harvested as described above. Labeled tumor cells at a concentration 
of 5 χ 104 cells in 0.2 ml of HBSS were injected i ν in mice receiving vehicle or 
batimastat (30 mg/kg i.p.) at -4 hr and at -4, +1, and +20 hr. At the times indicated (1, 4, 
24 hr) after tumor cell injection, mice were killed and the lungs removed and washed 
in 3 changes of 70% ethanol (11) Radioactivity in the lungs was determined in a 
gamma-counter (Beekman Gamma 5000, Palo Alto, CA) 
3 24 
Time (hr) 
Figure 1. Groups of b mice were injected ι ρ with batimastat at 30 mg/kg at the times shown 
(expressed relative to an injection of tumor cells at 0 hr m subsequent expenments) Blood samples were 
taken at 3 and 24 hr by caidiac puncture and the concentration of batimastat in the blood determined by 
ex-vwo bioassay. The values shown aie uncorrected for extraction efficiency 
Histology and immunocytochemistry analysis 
Classical histology was performed with hematoxihn-eosm-stained sections from 
tumor tissues fixed in 10% phosphate-buffered formalin and embedded in paraffin 
For immunocytochemistry, fresh tumor tissue was embedded in OCT (Miles, 
Elkhart, IN), and snap frozen in liquid nitrogen Five-micrometer cryostat sections 
were fixed in 100% acetone and immunostained with rat monoclonal antibodies 
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(MAbs) against m u r i n e CD45 ( M l / 9 3 4 , from ATCC, Rockville, MD), CD31 (MFC 13 3, 
courtesy of Dr A Vecchi, Mario Negri Institute, Milan, Italy), collagen IV (Chemicon, 
Temecula, CA), and laminin/CDw49f (Immunotech, Marseille, France) Sections were 
preincubated with rabbit serum and then sequentially incubated with optimal d i lu t ion 
of pr imary antibodies, with anti-rat biotinylated secondary antibody (Pharmingen, San 
Diego, CA) and avidin-biotin-peroxydase (Vector, B u r l m g a m e , CA) Each incubat ion 
step lasted 30 m i n and was followed by a 10 min Tns-buffered sahn wash Sections 
were then incubated with 0 03% H2C>2 and 0 06% 3 3' d i a m i n o b e n z i d i n e (BDH, Poole, 
UK) for 2-5 m m washed in tap water and counterstamed with hematoxihn 
Statistical analysis 
Mann-Whitney U test was used in all statistical analyses 
Table 2. Effect of batimastat on tuny colony formation by B16 BL6 melanoma 
T r e a t m e n t 
Vehicle 
Batimastat 
Vehicle 
Batimastat 
Schedule 1 
(hr) 
-4, +1, +24 
+48, +72 
-22,-3,+3, +10 
+18, +24, +48 
N u m b e r of 
mice with 
lung colonies 
9/9 
10/10 
10/10 
10/10 
M e d i a n 
l u n g 
colonics 
142 
45 
125 
30 
Range 
l u n g 
colonies 
97-163 
27-84 
46-218 
24-74 
P 2 
0 001 
0 001 
Tumor ι Ль 5 χ Ю* wen ιημφιΐ ι ν and autopsies performed 21 days later 
1) Batimastat was given ι ρ at a LOULUÜ ration of Wmy/kg Contiol mice ι ¿tewed the same amount 
of vehicle 
2) Compaied to vehicle treated miu 
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RESULTS 
Pharmacokinetics of batimastat 
Blood levels of batimastat were determined following both a single 30 mg/kg dose 
and following 2 30 mg/kg doses 5 hr apart, as used in subsequent lung colonisation 
experiments Levels of batimastat, as determined by the ex-vivo bioassay, ranged 
between 30 and 12 ng/ml over 24 hr following the single dose, and between 40 and 20 
ng/ml over 24 hours tollowing the repeated dose (rig 1) These values, when corrected 
for extraction efficiency (approx 50%), are over 20-fold higher than the IC3o of this 
inhibitor for collagenase (1 5 ng/ml) and the 92-kDa and 72-kDa typeIV collagenases (2 
ng/ml) On the basis of these results a dose of 30 mg/kg, ι ρ , once daily, was selected for 
the spontaneous metastasis and tumor growth experiments Subsequent studies have 
shown little detectable accumulation of batimastat in the blood following this ι ρ 
schedule (data not shown) 
Effect of batimastat on lung colonisation 
Batimastat, administered (30 mg/kg ι ρ ) -4, +1, +24, +48, +72 hr, relative to tumor 
cell administration at 0 hr, significantly inhibited (70%) the number of lung colonies 
(Table 2) Batimastat was also admistered at this dose and by this route using a second 
schedule (-22, -3,+3, +10, +18, +24, +48 hr) which increased the number of doses given 
immediately before and after the tumor cells Although this schedule resulted in a 
marginally increased inhibition (76%), the results showed the same degree of statistical 
significance as that obtained with the first schedule (Table 2) Experiments with more 
limited schedules have given more modest and less reproducible inhibition of 
colonisation (data not shown) 
The organ distribution and arrest of the B16-BL6 cells was followed by the injection, 
at 0 hr, of radiolabeled cells in mice receiving batimastat or vehicle at -4 hr or 
batimastat at -4, +1, and +20 hr (I ig 2) Groups of animals were killed at +1, +4, and 
+24 hr and radioactivity was measured in the spleen, h\er, kidneys and lungs 
Radioactivity levels were highest in the lungs, and the cell associated radioactivity in 
the spleen, liver, and kidney did not differ between groups In the lungs no differences 
were observed between the vehicle and batimastat group at +1 and +4 hr after tumor 
cell injection, but by 24 hr there was significantly less cell- associated radioactivity 
remaining in the lungs of the batimastat-treated (2 5% cell retention) compared to the 
control group (5 8% cell retention) Injection of batimastat at-4, +1, and +20 hr resulted 
in 2 6% cell retention at 24 hr Those results suggest thai batimastat does not affect the 
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arrest of cells in the lung but it does affect the retent ion of these cells, possibly by 
blocking extravasation. 
Control Batimastat Batimastat 
(-4hr) (-4,+1.+20hr) 
1 4 24 1 4 24 24 
Time after tumor cell injection (hr) 
Figure 2. Lung distribution of B16-BL6 
m batiiiiastat tieated mice. 4 χ 10^ 5-
I'^ll-lodo-I'dcoxyuridine-labclcd B16-
BL6 munnc melanoma cells were 
injected ι ν m mice j iwn vehicle or 
batimastat treatment (30 mg/kg, i.p ) 4 
In befoie and at -4, +7 and +20 hr 
Pei een tage of radioactivity of the 
originally injected cells remaining m the 
lungs was measured at 1 ( D ), 4 ( S ) 
and 24 < Ш ) hi after injection Input of 
injected cells = 18,540 ± 1,848 c.p m 
Results aie the mean ± SD of 5 lungs 
per gioup and are representative of 2 
different experiments. * p<0 05 
coiupaied to contiol 
2 0-, 
ρ (1 89 ± 1 0) 
τ ' 1 • 1 • 1 
8 10 12 14 16 18 20 
Days after transplant 
Figure 3. Effect of batimastat on the s с gì owl h of B16-BL6 Mice wei e injected s с (п=10) with 2 χ 
W' tumor cells. Batimastat (30 rug/kg, ι ρ ) starting at day of tiiiuoi tiansplaiil ( О ) or day 11 ( • ) 
Mice receiving the same amount of vehicle ( D ) Numbcis in paientliesis indicate tumor weight (mean g ± 
SD) at day 19 * p<0 02 compared to vehicle treated mice 
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Effect ofbatimastat on spontaneous metastasis 
To study the overall effect of the drug on the metastatic process, a spontaneous 
metastasis model was studied, with a primary B16-BL6 tumor in the foot-pad (Table 1) 
In the first experimental protocol, batimastat treatment was given daily from day 14 
and was stopped on the day of primary tumor excision This treatment resulted in a 
modest delay in primary tumor growth The tumors in this group were removed 2 
days later than those of the control group, by which time they had reached a similar 
size (range 110-530 mg, calculated weight) Treatment with batimastat for this period 
before surgery did not reduce the number of lung metastases, but did result in a 
significant decrease in the size of the lung metastases (median calculated weight 7 1 
mg, range 0 5-73 3 mg) compared to those of the vehicle- treated animals (median 
calculated weight 29 8 mg, range 1 0-209 8 mg) (Table 1) 
In the second experimental protocol, batimastat treatment was given daily from the 
day of primary tumor excision until the end of the experiment on day 44 This post­
surgical treatment schedule resulted in a small reduction in the number of animals 
with lung metastases (11 of 12 in the control group vs 9 of 13 in the batimastat-treated 
group) and a non-significanl decrease in the median number of lung metastases (Table 
II) As in the first experiment, there was a significant reduction in the size of lung 
metastases in the batimastat-treated group (median calculated weight 8 4 mg; range 1 0-
57 0) compared with the vehicle treated group (median calculated weight 35 1 mg, 
range 1 0-224 0) 
Effect of batimastat on subcutaneous tumor growth 
The results from the spontaneous metastasis experiment suggested that batimastat 
could inhibit tumor growth Mice were injected s с with B16-BL6 cells and treated with 
vehicle or batimastat daily from day 1 to day 19 A third group was treated with 
batimastat daily from day 11, by which time the primary tumor was palpable (mean 
tumor weight ± SD, 38 ± 23 mg), to day 19 The mean tumor doubling time was 15 + 08 
days in the vehicle-treated animals, compared to 2 5 ± 0 8 days and 2 1 ± 0 4 days in the 
animals receiving batimastat from dayl and from day 11 respectively (Fig 3) At day 19, 
the weight of primary tumors in the group receiving batimastat from day 1 (mean 
tumor weight ± SD, 0 8 ± 0 3 g) was significantly lower than that in the vehicle-treated 
group (mean tumor weight ± SD, 1 89 ± 1 05 g) 
Histological and lmmunocytochemical analysis were performed on treated and 
untreated B16-BL6 tumors Independently from treatment, tumors were characterized 
by solid cellular growth and absence of intratumoral sformai structures Furthermore, 
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the morphology of batimastat-treated neoplastic cells was similar to that in the vehicle-
treated group Analysis of the immune reactive infiltrate at the tumor site, performed 
with anti-CD45 on cryostats sections of the same tumors, showed that all the tumors 
were virtually devoid of reactive infiltrate Finally, no differences between vehicle and 
batimastat treatments were found either in tumoral and pentumoral 
neovascularization using anti CD31 to stain endothelial cells, or in the composition of 
thickness of the vascular basement membranes with anti-laminin/CDw49f and 
collagen IV (data not shown) 
Effect of batimastat on tumor cell proliferation in vitro 
To investigate the possibility that batimastat might be directly cytostatic or cytotoxic 
to B16-BL6 cells, subconfluent monolayers of these cells were treated with batimaslat al 
a range of concentrations and proliferation was subsequently assessed by "Ή-thymidine 
incorporation Batimastat had no significant effect on the rate of B16-BL6 proliferation, 
even at concentrations 50-fold higher than those measured in the blood (Table 3) 
Table3. Effect of batimastat on the proliferation of ΒΊ6 BL6 ccll^ in vitro 
Batimastat (ng/ml) 
idioactivity (dpm) 
(mean ± SD) 
303,803 ± 7,637 
305,035 ±10,072 
288,051 ± 11,145 
271,775 ±6,806 
279,568 ± 6,488 
256,065 ± 7,704 
V EtOH 
Control 
119 
119 
112 
106 
109 
100 
1500 
500 
150 
50 
Cell Control 
EtOH Control 
B16-BL6 melanoma сеііь were seeded in culture and treated with batiniabtal for 22 hr at 
37°C Results represent the mean +SD of a duplicate 
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DISCUSSION 
Our results have shown that the matrix metalloproteinase inhibitor, batimastat, is 
effective in various aspects of tumor formation of the B16-BL6 mouse melanoma 
model. Batimastat inhibited lung colonization by B16-BL6 cells and significantly 
affected the growth of the primary tumor and the size of spontaneous metastases in 
the lung. The origin of the matrix metalloproteinases in B16-BL6 tumor remains 
unresolved. Analysis of B16-BL6 cell lysates and conditioned media revealed only low 
levels of 72-kDa type IV collagenase (data not shown). However, others have shown 
this to be the principal degradative enzyme in these tumor cells (16). Various studies of 
human clinical tumor tissue have revealed that tumors can induce the expression of 
matrix metalloproteinases in adjacent non-tumor tissue (3,19). It is quite possible that 
the B16-BL6 cells may utilize such stromal source of metalloproteinases to break tissue 
barriers. 
Although batimastat could markedly reduce lung colonisation (experimental 
metastasis), it failed to cause a significant reduction in the number of spontaneous 
metastases formed from a primary tumor. The process of B16-BL6 lung colonisation 
has been studied electron microscopically. Tumor cell arrest, endothelial cell retraction 
and basement membrane breakdown have been documented (5). Inhibition of this 
process by the related matrix metalloproteinase inhibitor SC4463 has been 
demonstrated previously by Reich et al. (1988). Our study suggests that batimastat acts, 
not bypreventing tumor cell arrest but rather by inhibiting breakdown of the basement 
membrane. In contrast, the process of spontaneous metastasis is significantly more 
complex, involving regional spread and dissemination through blood and lymphatic 
systems. Unlike lung colonisation, this process occurs over weeks. The failure of 
batimastat to significantly reduce the incidence of spontaneous metastases may be due 
to an inability to block lymphatic spread. 
Although treatment with batimastat did not cause any significant reduction in the 
number of lung metastases, both pre-surgery and post-surgery treatments resulted in a 
significant decrease in the size of the metastases. Analysis of the result from pre-
surgery treatment is complicated by the fact that batimastat was admistered in 
suspension form, while pharmacokinetic analysis has shown that batimastat when 
administered i.p. forms a depot, giving rise to measurable systemic concentrations for 
up to 14 days (data not shown). Therefore, it is likely that batimastat remained present 
systemically for some time after surgery in this group and was thus able to affect 
growth of secondary tumors. 
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The ability of batimastat to inhibit B16-BL6 tumor growth was confirmed in a study 
of the effects of the drug on s с tumor growth The means by which batimastat inhibits 
the tumor growth have not been established In vitro prohfration assays revealed that 
the drug exhibits no direct cytostatic or cytotoxic activity towards the B16-BL6 cells 
Although it is possible that the drug exerts cytostatic activity η vivo, it appears more 
likely that batimastat prevents tumor growth by limiting the ability of the tumor to 
breakdown adjacent tissue using matrix metalloproteinases Alternatively, batimastat 
may act by inhibiting neovasculansation We did not, however, observe marked 
changes in B16-BL6 tumor morphology or vascularity 
Studies with a form of TIMP derived by cartilage have shown that this native 
inhibitor of matrix metalloproteinases can block tumor-induced neovasculansation 
(18) Studies with tumor cells transfected with TIMP-2 have shown that local 
production of TIMP-2 by these cells markedly limited their growth in vivo and 
suppresses their ability to invade surrounding tissue (9) Histological analysis of these 
tumors has indicated that the production of TIMP-2 had caused the deposition of dense 
fibrotic tissue and that this effectively limited growth and spread No analysis of the 
extent of vascularization was made 
Previous studies with batimastat have demonstrated the ability of this inhibitor to 
resolve experimental malignant ascites, in part by inducing the stroma! encapsulation 
of the malignant cells (6) A more detailed analysis is likely required to detecta similar 
response in batimastat-treated B16-BL6 melanoma 
Our findings indicate that inhibitors of matrix metalloproteinases, whether natural 
or synthetic, should be thought of as more than anti metastatic agents in addition to 
preventing tumor spread, these agents may perhaps show clinical utility in limiting 
tumor growth 
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INTRODUCTION 
Metastasis is a multistep process in which a metastatic tumor cell detaches from the 
primary tumor, invades the surrounding tissues, passes through supporting structures 
such as interstitial stroma and extracellular matrix, and enters the lymphatic or blood 
circulation (42) Only a few of the neoplastic cells released into the circulation, that 
survive hemodynamic pressure and host defense mechanisms, will form metastases 
The arrest of tumor cells in the capillary bed of secondary organs through an 
interaction with vascular or lymphatic endothelium and subendothelial basement 
membrane is followed by their extravasation into the tissue parenchyma, and then 
micro-metastasis formation Therefore cell-cell and cell-substrate adhesions occur at 
different moments in this process With the recent identification and characterization 
of cell surface molecules, it has become of particular interest to clarify their role in 
tumor progression and metastasis (1) 
The adhesion response of tumor cells can be mediated by several receptors that 
belong to four major families Cadherins (52), immunoglobulin super family (55), 
integrins (10), and selectins (36) Other adhesion molecules, such as the glycoprotein 
CD44, the lectin-hke Lu-ECAM-1 and the 67-kD laminin receptor, are reported to play 
an important role in metastasis (9,24,56) The expression (or down regulation) of 
adhesion molecules has been associated to the malignant phenotype and implicated in 
tumor-host cell recognition 
A major mechanism of tumor cell extravasation consists of rapid attachment to the 
endothelium, followed by endothelial cell (EC) retraction or disruption of the 
endothelial layer and migration of tumor cells to the subendothehal matrix with 
dissolution of the basement membrane (13) EC recognition precedes the extravasation 
of circulating tumor cells (27) 
Preferential adhesion of metastatic cells to EC from target organs has been described, 
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suggesting that endothehal-tumor cell recognition plays a role in metastasis homing to 
specific sites (4,38) Tumor and EC surface adhesion structures, including lectins, 
proteoglycans and integrins, have been proposed as mediators of this interaction, but 
their specific roles in metastasis formation still need to be elucidated (1,6,43,47,56) 
Vascular changes can easily influence the interaction and thus the whole metastatic 
process (6,54) Here we will address adhesion mechanisms that regulate tumor-EC 
interactions and metastasis formation under inflammatory stimuli 
Cytokines affect adhesive properties of endothelial cells and metastasis 
Endothelial cells (EC) represent one of the major targets of inflammatory cytokines 
that can alter their functional status (12,34) The availability of EC cultures has allowed 
to study their interaction with normal and transformed cells It has been shown that 
interleukin-1 (IL-1), and tumor necrosis factor-α (TNF) increased the expression of 
adhesion molecules on EC surface resulting in increased basal adhesion of leukocytes 
(41) The adhesion of human tumor cells of different histological types and origin was 
enhanced to cytokine-activated human umbilical EC (14,28,44) 
To study the relevance of these findings in metastasis, the effects of IL-1 and TNF 
were examined in vivo In nude mice injection of IL-1 α or IL-lß before ι ν injection of 
radio-labeled human tumor cells did not influence the ability of tumor cells to reach 
the target organ but significantly increased their retention in the lung at 4 and 24 hours 
(20) Thus, more lung colonies were produced in mice given IL-1 or TNF than in 
vehicle treated animals (20) Augmentation of tumor spread and metastases by IL-1 
and TNF has been described m different tumor systems human tumors in nude mice 
and murine tumors in syngeneic mice, tumors that formed metastases to the lung, 
liver and bone or intraperitoneal dissemination (3,5,7,28,33,39) However cytokine 
treatment did not induce metastasis formation by tumor lines that were not metastatic, 
nor changed their metastatic homing (5), indicating that they quantitatively modulate 
metastasis formation, without changing the intrinsic metastatic properties of tumor 
cells 
The increases in tumor cell adhesion to IL-1-nctivaled EC and in lung colony 
formation in IL-1-treated mice were specifically inhibited by the IL-1 receptor 
antagonist (IL-lra) (11) A 100-fold excessof IL-lra was necessary to completely block the 
effect of IL-1 on tumor cell adhesion and metastasis formation, suggesting that higher 
concentrations of IL-lra are needed to saturate IL-1 receptors and induce antagonism 
(2,17) 
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Figure 1 Adhesion behavior of AÌ75M melanoma and HT29M colon carcinoma (modifnd from 
Cmvnzzi 11 al Î99ÎJ Pam I A) The adhesion of tumor cells was evaluated on surfaces coated with soluhh 
VCAM 1 and E sekctin HSA= human ν ι um albumin Tumor сеііъ wire incubated with the respective 
monoclonal antibodies foi W minutes bifore the adhesion experiments Panel B) Rolling and panel О 
adlusion of tumoi cellsto untreated and IL 7 treated EC were analyzed under shear stress И 0 dynes/cm2) 
Stimulated EC were incubated m medium containing monoclonal antibodies for 30 minutes before the 
adhesion experiment 
IL-lra also inhibited hpopolysacchande (LPS) increased experimental metastasis 
formation LPS is a nonspecific inflammatory stimulus that triggers a cascade of host 
derived mediators responsible for its proinflammatory effects The specific effect of IL 
Ira indicates that host-produced IL-1 plays a role in the increase of metastasis by LPS 
(11) In that study the block of augmented tumor cell adhesion to activated EC was 
associated with inhibition of adhesion molecules expression on EC (11) These findings 
support the theory, discussed below, that the increase of lung colonies by II -1 is at least 
partially mediated by augmented expression of adhesion proteins 
Endothelial cell adhesion molecules in the metastatic process 
The normal equivalent of a tumor cell that extravasales during metastasis is a 
leukocyte that leaves the bloodstream early in an inflammatory and i m m u n e 
response Inflammatory cytokines stimulate leukocyte adhesion on EC and this is 
mediated by the induction of multiple FC adhesion molecules (41) The activation of 
EC results in the induction of or an increase in the expression of the intercellular 
adhesion molecule-1 (ICAM-1), the vascular cell adhesion molecule-1 (VCAM-1), and 
E-sclectin (8,18,40), all responsible for the interaction of leukocytes with EC 
Antibodies against these molecules can be used to study their role in tumor cell 
adhesion to LC Such antibodies totally or partially inhibit the increase of tumor cell 
adhesion to cytokine-activnted EC I Iowever, different tumor types preferentially use 
different adhesion pathways Tor example, selectin-carbohydrate interactions 
underlie the adhesion of colon-relnted carcinomas (15,29,45,51), whereas VCAM-1-
lntcgrin interactions mediate the adhesion of melanomas and osteosarcomas 
(29,35,45) 
These observations were further confirmed by adhesion of tumor cells on 
immobilized soluble proteins Representative results with the A375M melanoma and 
HT29M colon carcinoma are shown in Figure 1, panel A The melanoma cells did not 
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adhere to surface coated with E-selectin but did adhere to VCAM-1 and this adhesion 
was inhibited by the anti-VCAM-1 antibody, or by treating the cells with an anti-a4ßl 
(VLA-4) integrin antibody. HT-29M colon carcinoma cells, on the other hand, did not 
adhere to surface coated with VCAM-1 but did adhere to E-sclectin and this adhesion 
was partially inhibited by an antibody against E-selectm, or by treating the cells with 
anti-sialyl-Lex or sialyl-Le3 antibodies. 
Although there is evidence that E-selectin recognizes specific carbohydrate 
structures such as sialyl-Lex or sialyl-Lea on tumor cells (51), the counter-receptors for 
E-selectin have not yet been fully identified. We have reported that one monoclonal 
antibody (MBr8), which binds Lewis fucosylaled type I on ЫТ-29М colon carcinoma 
blocks its adhesion on IL-1 activated EC (15) as well as on E-selectin coated syrface 
(Figure 1, panel A). The same antibody given in vivo inhibited the augmented 
retention of colon cells in the lung of nude mice treated with IL-1 (15) Together these 
results suggest that more than one carbohydrate group is responsible for the binding of 
colon cells to E-selectin. 
The adhesion molecule VCAM-1 is the endothelial ligand for VLA-4 integrin 
Studies on a series of melanoma clones have shown that expression of VLA-4 
integrin varied with the ability of the clones to adhere to FC (35). Antibodies directed to 
VLA-4 or VCAM-1 inhibited the adhesion of melanoma cells to IL-1-activated EC 
(35,45). While these results strongly support a role of VCAM-1/VLA-4 in 
melanoma/ЕС interactions, it remains to be demonstrated that VLA-4 expression on 
melanoma cells is associated with their metastatic potential 
Leukocyte rolling and adherence on EC has been reproduced in vitro in 
dynamic flow environment, and the roles of the adhesion molecules that mediate 
these interactions have been identified (30,50). The first interaction of leukocytes with 
the vascular wall is weak (rolling) and mediated by seleclins, followed by a strong 
(sticking) interaction mediated by integrins (25,31); firmly attached leukocytes, then 
transmigrate through the endothelium 
We have investigated the interaction of tumor cells on cullured EC under dynamic 
flow conditions (22). Tumor cell lines studied under flow conditions adhered to IL-1 
activated EC. However two different mechanisms characteri7.ed the adhesion of tumor 
cells to activated EC For example some types of carcinoma cells adhered on F.C with 
rolling whereas melanoma and osteosarcoma firmly adhered to activated FC without 
rolling (22). Using monoclonal antibodies against adhesion proteins wc found that E-
selectin plays a major role in mediating rolling and adhesion of HT-29M colon 
carcinoma, whereas VCAM-1 was involved in the adhesion of A375M melanoma cells 
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on activated EC (Fig 1) These findings suggest that under flow conditions, E-selectin 
has a role in tumor cell rolling/adhesion on EC whereas VCAM-1 only mediates 
tumor cells adhesion 
In these studies above ICAM-1 did not play a real role in the adhesion of tumor 
cells to cytokine-activated EC This is most probably because those tumor cells lack the 
counter receptors for ICAM-1 such as LFA-1 and Mac-1 (16) However ICAM-1 plays an 
important role in tumor progression and metastases ICAM-1 is expressed on a 
number of different tumor types and its expression can be modulated by cytokines 
(21,48) In human melanomas ICAM-1 expression has been associated with tumor 
malignancy and progression (26,37) Finally, ICAM-1 also mediates the host i m m u n e 
recognition of tumor cells (32,53), and this is associated with a favorable prognosis 
Soluble forms of ICAM-1 (sICAM-1) have been described in normal human serum 
(46), and elevated levels have been found in serum of patients with inflammatory and 
neoplastic diseases (19,23,49) We have shown that A375M melanoma expresses ICAM 
1 on the cell surface, and secretes ICAM-1 after stimulation with the cytokines IL-1, 
TNF and interferon-γ (21) In addition we have found sICAM-1 in sera of nude mice 
transplanted with human tumors (21) The levels of ICAM-1 in the serum of nude 
mice bearing melanomas were related to the tumor burden and were higher in 
animals treated with cytokines (Giavazzi et al, personal observation) Further 
investigations might usefully focus on the role of ICAM-1 in response to host-derived 
cytokines and its relevance in the control of tumor progression and metastasis 
CONCLUSIONS 
Multiple mechanisms seem to regulate the interactions between tumor cells and 
the microvasculature during tumor dissemination and metastasis IL-1 and TNF 
induce tumor spread and increase metastasis formation in different tumor systems 
Tumor-induced and host-induced cytokines can contribute to tumor malignancy The 
increase in metastases appears related to the initial arrest and extravasation of tumor 
cells at the capillary bed of secondary organs This is supported by in vitro results 
showing greater tumor cell adhesion on cytokine-activated EC Since IL-1 and TNF 
increased the expression of cell surface adhesion molecules that mediate tumor cell 
adhesion on FC, it appears that the interaction of tumor cells with specific EC ligands is 
important in the cytokine-induced increase of metastases 
Distinct adhesion molecules may play different roles in the various phases of 
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tumor cell interaction with endothelial and subendothelial substrates Moreover 
different tumor cell types appear to use different adhesion proteins for adhesion and 
invasion, and specific adhesion patterns may influence metastasis homing in different 
districts A better understanding of these adhesion mechanisms involved in tumor-EC 
interaction is still necessary, but the indentification of specific recognition structures 
on tumor cells and EC surface offers interesting targets for the diagnosis and treatment 
of metastatic disease 
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Summary 
Summary 
In this thesis we present a number of studies on the involvement of cytokines, 
adhesion molecules and matrix metalloproteinases (MMP) in melanoma progression 
and metastasis 
The interaction of tumor cells with endothelial cells (EC) is an important step in 
metastasis formation These interactions are supported by adhesion molecules on both 
cell types, which can be altered by infiamma tory cytokines such as interleukin-l (IL-1) 
and tumor necrosis factor (TNF) Following the arrest of tumor cells at the capillary 
bed, tumor cells migrate through EC and extracellular matrix (ECM) and invade 
secondary organs Tumor cell migration requires proteinases to break down the ECM 
The aim of our studies was to elucidate some aspects of these complex mechanisms 
and develop experimental therapies to block tumor cell adhesion to EC and ECM 
degradation by tumor cells, which means inhibition of metastasis formation 
Chapter 1 gives an introduction and overview of the literature, focussing on the 
role of cytokines m tumor-endothelial cell interaction, and the role of ΜΜΓ and their 
inhibitors in metastasis formation 
In Chapter 2 we describe how IL-1-mediated experimental metastases from A375M 
human melanoma in nude mice can be blocked by the recombinant h u m a n 
interleukin-l receptor antagonist (II-Ira) IL-1 ra significantly inhibited the response to 
IL-1 when it was administered simultaneously with or 1 to 3h before IL-1 in vitro 
incubation of IL-1-activated EC with IL-1 ra prevented the increased adhesion of Λ375Μ 
melanoma cells In the same experimental conditions, IL-lra inhibited the increased 
expression of intracellular and vascular adhesion molecule-1 (ICAM-1 and VCAM-1) 
and E-selectin on IL-1 activated EC Lipopolysacchande, an II -1 inducer, increased 
metastasis formation byA375M cells in the lungs of nude mice II Ira injected together 
with or lh after lipopolysacchande prevented this increase in metastasis formation, 
suggesting a role for host-produced II -1 
The study presented in Chapter 3 reports the involvement of the a4ßl ìntegrin 
(VLA-4) in IL-1 augmented tumor colonies in the lungs of nude mice with human 
melanoma A375M A375M cells express high levels of VLA-4 and preferentially adhere 
to VCAM-1 coated surfaces, the ligand for VI A-4 on EC This adhesion was inhibited 
by treating A375M cells with mAb to VLA-4 Mice injected with IL-1 before A375M 
injection showed increased colony formation in the lung Pretreatment of A375M with 
mAb to VLA-4 completely prevented the IL-1-induced increase in lung colony 
formation Using two metastatic clones (2/4 and 2/60), which express different levels of 
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VLA-4, we showed that only VLA-4 bearing cells adhered to VCAM-1 coated surfaces 
and formed larger numbers of lung colonies in IL-1 treated nude mice, and this could 
be inhibited when cells were pretreated with mAb to VLA-4 These results 
demonstrate the functional role of VLA-4 on melanoma cells in IL-1-mediated lung 
colony augmentation, most probably involving the interaction of tumor cells with 
VCAM-1 on activated EC 
Having found that mAb directed against VLA-4 on melanoma cells and IL-lra 
administration to nude mice can inhibit the IL-1-induced increase in tumor colonies 
in the lungs we investigated (Chapter 4) whether the constitutive expression of IL-1 
influences the adhesive potential of transformed melanoma cell lines A37SP h u m a n 
melanoma was transfected with an IL-1 gene Two colonies, colony-3 and colony-6, that 
respectively do not and do express and release IL-1 were selected Both colonies 
adhered to the same extent to resting ГС Pre-treatmenl of EC with conditioned 
medium (CM) from colony-6, but not from colony-3, resulted in increased adhesion of 
A375P cells to EC, and induced the expression of ICAM-1, VCAM-1 and E-selectin on 
EC The increased adhesion of melanoma cells to EC, and the induced adhesion 
molecule expression on EC could be blocked by adding IL-lra to the EC monolayer Pre­
treatment of EC with monoclonal antibodies to VCAM-1 and E-selectin prevented the 
colony-6-CM-induced adhesion to respectively A375Pmelanoma cells and IIT-29 colon 
carcinoma cells //; vivo, intravenous injection of colony-6 cells in nude mice 
increased the expression of VCAM-1 on lung microvascular EC The retention of 
radiolabeled A375Pcells in the lung was increased in nude mice primed with colony-6 
cells, but not colony-3 cells, injected 6h earlier These results demonstrate that IL-1 
produced constitutively by transformed A375P melanoma cells is functionally active, 
inducing cell adhesion molecules on EC that increase their adhesiveness for tumor 
cells and increase tumor cell retention in the lung of nude mice 
It has been reported that the serum of melanoma patients contain elevated levels of 
soluble ICAM-1, however, the source of this ICAM-1 was unclear We studied (Chapter 
5) the expression of cell surface ICAM-1 and the release of soluble ICAM-1 by the 
A375M human melanoma cell line treated by inflammatory cytokines Unstimulated 
cells express ICAM-1 on their cell surface, but do not secrete significant levels of 
soluble ICAM-1 Treatment of A375M cells with IL-1, IL 6, TNF or γ-interferon (IFN-γ) 
all increased cell surface ICAM-1 expression and only IL-6 did not cause the release of 
soluble ICAM-1 Serum from nude mice bearing subcutaneous A375M h u m a n 
melanoma tumors was found to contain soluble human ICAM-1 ICAM-1 levels 
showed a positive correlation with tumor weight Because our ELISA does not detect 
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murine ICAM-1, the finding of soluble ICAM-1 in serum of nude mice bearing 
melanoma tumors confirms that the human tumor is the source of ICAM-1 The 
release of ICAM-1 from melanomas, in response to host-derived cytokines, may have 
relevance to the immune recognition of the tumor Whatever the functional role of 
cell surface or soluble ICAM-1 in tumor progression, the detection of soluble ICAM-1 
in serum offerss a potential prognostic marker for malignant melanoma 
In Chapter 6 we describe a treatment designed to prevent the degradation of ECM 
and the invasion of surrounding tissues by tumor cells We tested the synthetic MMP 
inhibitor batimastat for its ability to inhibit growth and metastatic spread of the B16-
BL6 murine melanoma in syngeneic mice Intraperitoneal injection of batimastat 
inhibited lung colony formation by B16-BL6 cells after intravenous injection The 
effect of batimastat was also tested on spontaneous metastases of mice bearing B16-BL6 
melanoma in the hind footpad after surgical removal of the primary tumor 
Batimastat was administered twice a day from day 14 to day 28 (pre-surgery), or from 
day 26 to day 44 (post-surgery) Neither protocol significantly influenced colony 
formation, but they both reduced the weight of metastases Hnally, batimastat was 
tested for its ability to influence subcutaneous growth of B16-BL6 melanoma Daily 
doses, starting on the day of tumor transplantation, resulted in significant slowing of 
growth, whereas treatment started when the tumor was advanced, reduced its growth 
only marginally Our findings indicate that inhibitors of MMPs might serve as more 
than anti-metastatic agents besides preventing tumor spread, these agents may show 
some clinical utility in limiting tumor growth 
In Chapter 7 we review the role of inflammatory cytokines and adhesion molecules 
in metastasis formation This chapter can be considered a general discussion 
In conclusion, our studies demonstrate that exogenous and tumor-produced IL-1 
increase the adhesion of melanoma to EC in vitio, inducing tumor spread and 
increasing metastasis formation in our melanoma tumor system which can be blocked 
with recombinant human IL-lra The increase in melanoma adhesion to EC and 
metastasis formation is due to IL-1-induced adhesion molecules on EC like ICAM-1, 
VCAM-1 and E-selectin Melanoma adhesion to activated EC is mediated by the VLA-
4/VCAM-l pathway which probably play a crucial role in melanoma metastasis 
formation Pre-treatmcnt of melanoma cells with antibodies to VLA-4 prevented 
melanoma adhesion to EC in vitro and the augmentation of lung colonies m vivo 
ICAM-1 can be shed by melanoma cells in response to cytokines, and the cell surface 
ICAM-1 left may be inadequate for effective recognition by cytotoxic lymphocytes The 
functional role of cell surface or soluble ICAM-1 in tumor progression is not yet clear 
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To investigate the migration of tumor cells through EC and ECM, we investigate the 
anti-metastatic effect of a synthetic inhibitor of MMPs, batimastat Our findings 
indicate that batimastat can prevent and reduce tumor spread and growth 
Our understanding of the involvement of adhesion molecules and MMPs in the 
metastatic process of tumor cells in general, and melanoma cells in particular, is still 
incomplete, but our growing knowledge offers hope for novel strategies to inhibit 
tumor spread 
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Samenvatting 
Samenvatting 
In dit proefschrift is een aantal artikelen opgenomen met als wetenschappelijk 
thema de verwikkeling van cytokinen, adhesie moleculen en matrix 
metalloproteinasen (MMP) in de tumorprogressie en uitzaaiing van melanomcn 
De interactie van tumorcellen met endoteelcellen (ЕС) іь een belangrijke stap in de 
vorming van metastasen Adhesiemoleculen op beide cel-soorten, waarvan de 
expressie veranderd kan worden onder invloed van cytokinen zoals interleukine-1 
(IL-l)en tumor necrosis faktor (TNF), zijn hierbij betrokken Nadat de tumorcellen tot 
stilstand zijn gekomen in capillaire bloedvaatjes, moeten deze door de EC en de 
extracellulaire matrix (ECM) migreren om de betrokken organen binnen te dringen 
Om te migreren hebben deze cellen proteinasen, (eiwit-splitsende enzymen), nodig 
voor het afbreken van ECM Het doel van onze studies was om meer duidelijkheid te 
scheppen in deze zeer complexe mechanismes en om een experimentele therapie te 
ontwikkelen om tumorcel-ЕС adhesie en ECM- afbraak door tumorcellen te 
voorkomen 
In Hoofdstuk 1 wordt na een korte inleiding een overzicht van de literatuur 
gegeven, met speciale aandacht voor de rol die cytokinen bij tumorcel-ЕС interactie 
spelen, en tevens voor de rol van MMP en hun remmers bij de vorming van 
metastasen 
In Hoofdstuk 2 wordt beschreven dat de IL-1 geïnduceerde experimentele 
metastasen van de humane melanoom cellijn A375M in naakte muizen geblokeerd 
kan worden door de humane interleukine-1 receptor antagonist (IL-lra) IL-lraremt de 
werking van II-1 aanzienlijk als het samen met IL-1 of 1 tot 3h voor de IL-1 injectie 
werd toegediend /;; vitro vonden wij dat de verhoogde adhesie van A375M 
melanoomcellen op IL-1 geactiveerd EC door de incubatie van geactiveerd CC met IL-
lra geremd kan worden Bij dezelfde experimentele omstandigheden werd de 
verhoogde expressie van intercellulair adhesie molecuul-1 (ICAM-1) en vasculair 
adhesie molecuul-1 (VCAM-1) en E-selectine op IL-1 geactiveerd EC geremd door IL-
lra Lipopolysacchnde, dat IL-1 induceert, bevordert de vorming van A375M 
metastasen in de longen van naakte muizen De injectie van IL-lra tegelijkertijd of lh 
na het toedienen van lipopolysacchride remt de metastasenvorming Dit suggereert 
een rol van het door de gastheer geproduceerde IL-1 bij de vorming van metastasen 
De studie die in Hoofdstuk 3 gepresenteerd wordt laat de betrokkenheid van de 
a4ßl integrine (VLA-4) zien bij de door IL-1 gestimuleerde metastasering van humane 
A375M melanoomcellen in de longen van naakte muizen A375M cellen hebben een 
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hoog VLA-4 expressie-niveau en hechten bij voorkeur op oppervlaktes bedekt door 
VCAM-1, dat de ligand voor VLA-4 op EC is Deze hechting wordt geremd als A375M 
cellen behandeld worden met monoclonale antilichamen tegen VLA-4. Muizen die 
voor de A375M injectie met IL-1 behandeld werden, hadden een verhoogde mate van 
uitzaaiing in de longen Deze verhoogde metastasevorming werd compleet geremd als 
A375M cellen voor de injectie behandeld werden met monoclonale antilichamen 
tegen VLA-4 Twee klonen (2/4 en 2/60) met verschillend VLA-4 expressie-niveau 
werden voor verdere studie gebruikt We vonden dat alleen de VLA-4 positieve kloon 
op VCAM-1 gecoat plastic hecht, en meer metastasen in de longen van IL-1 behandelde 
naakte muizen vormt De metastasevorming kon geremd worden wanneer de cellen 
voorbehandeld werden met monoclonale antilichamen tegen VLA-4 Deze resultaten 
tonen aan dat VLA-4 een functionele rol speelt bij de door IL-1 geïnduceerde 
metastasevorming in de long Dit komt hoogstwaarschijnlijk door de interactie van de 
tumorcellen met het op geactiveerd EC aanwezige VCAM-1 
Nadat we gevonden hadden dat de behandeling van melanoomcellen met 
monoclonale antilichamen tegen VLA-4 en van naakte muizen met IL-lra de 
verhoogde metastasevorming in de longen van IL-1 behandelde muizen remt, 
onderzochten wij verder of het adhesie-niveau beïnvloed wordt als de humane A375P 
melanoom cellijn getransfecteerd wordt met een gen dat voor IL-1 codeert (Hoofdstuk 
4) Twee klonen, kloon-3 en -6, die respectievelijk niet en wel IL-1 produceren, werden 
geselecteerd Beide klonen bleken op een overeenkomstige wijze op niet geactiveerd 
ГС te hechten. Behandeling van de EC met geconditioneerd kweekmedium (CM) van 
kloon-6, maar niet van kloon-3, resulteerde in een verhoogde hechting van A375P 
cellen aan EC Deze behandeling had ook een verhoogde ICAM-1, VCAM-1 en E-
selectine expressie op EC tot gevolg De verhoogde adhesie van melanoomcellen aan 
EC, en de verhoogde expressie van adhesie moleculen op EC konden verlaagd worden 
als er IL-lra aan EC toegevoegd werd De behandeling van EC met monoclonale 
antilichamen tegen VCAM-1 en E-selectine remde de door CM van kloon-6 verhoogde 
hechting aan EC van respectievelijk A375P melanoom en HT-29 colon 
carcmoomcellen De intraveneuze injectie van kloon-6 cellen in naakte muizen 
verhoogde de VCAM-1 expressie op EC van capillaire bloedvaatjes in de long De 
uitzaaiing van radioaktief gelabelde A375P cellen in de long was verhoogd in naakte 
muizen die 6 uur eerder ingespoten waren met kloon-6, maar niet met kloon-3 Deze 
resultaten laten zien dat het door de getransfecteerde A375P melanoomcellen 
geproduceerd IL-1 functioneel aktief is De verhoogde expressie van adhesiemoleculen 
op EC bevordert de hechting van tumorcellen hieraan, hetgeen een verhoogde 
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metastasevorming tot gevolg heeft 
Het is bekend dat in serum van melanoompatienten hoge concentraties van niet 
cel-gebonden ICAM-1 aanwezig is De herkomst hiervan was voorheen nog niet 
duidelijk In Hoofdstuk 5 hebben wij de expressie van cel-gebonden ICAM-1 en de 
uitscheiding van ICAM-1 door de humane A375M melanoomcelhjn bestudeerd 
Tevens onderzochten wij hoe de expressie en uitscheidmg door cytokinen beïnvloed 
kan worden Melanoomcellen hebben ICAM-1 op hun celmembraan, maar zij 
scheiden geen significante hoeveelheden ICAM-1 uit Behandeling van A375M cellen 
met IL-I, IL-6, TNF of γ-interferon (IFN-γ) verhoogt het ICAM-1 expressie-niveau 
Alleen IL-l,IL-6 en IFN-γ brachten uitscheiding van niet cel-gebonden ICAM-1 teweeg 
Naakte muizen met onderhuidse A375M tumoren hadden met cel-gebonden ICAM-1 
in hun serum Er was een positieve correlatie tussen ICAM-1 concentraties in serum 
en het gewicht van de tumor Omdat onze ELISA geen muis ICAM-1 detecteert, 
konden wij met zekerheid bevestigen dat de bron van ICAM-1 in serum van naakte 
muizen met onderhuidse tumoren, de humane tumor is Het uitscheiden van niet 
cel-gebonden ICAM-1 door melanoomcellen, in reaktie op cytokinen afkomstig van de 
gastheer, zou van belang kunnen zijn bij de herkenning van de tumor door het 
immuunsysteem Wat ook de funktie van cel-gebonden en niet cel-gebonden ICAM-1 
bij de tumorprogressie mag zijn, de ICAM-1 concentratie in serum is een goede 
merkstof voor de prognose van het melanoom 
In Hoofdstuk 6 hebben wij een behandelingswijze bestudeerd om de degradatie van 
ECM en omringend weefsel door tumorcellen te voorkomen Hierbij hebben wij de 
syntetische MMP remmer "batimastat" uitgetest om de groei en uitzaaiing van de 
muis melanoom cellijn B16-BL6 in syngene muizen tegen te gaan Intraperitoneale 
toediening van batimastat remt de uitzaaiing van B16-BL6 cellen in de long als deze 
cellen in een staartader geïnjecteerd werden Het effect van batimastat is ook getest op 
de vorming van spontane metastasen De B16-BL6 melanoomcellen werden in het 
voetbed van de achterpoot ingespoten Deze werd geamputeerd als de tumor ongeveer 
1 cm3 groot was Batimastat werd twee maal daags toegediend van de 14e tot en met de 
18° dag (pre-amputatie), of van de 26e tot en met de 44e dag (post-amputatie) Beide 
protocollen hadden geen effect op de hoeveelheid metastasen die in de long gevormd 
werden, maar het gewicht van de individuele metastasen was verminderd Tenslotte 
werd batimastat ook getest op de onderhuidse groei van het B16-BL6 melanoom 
Dagelijkse toediening vanaf de dag van de tumonnplantatie zorgde voor een 
significante remming van de tumorgroei De groei werd maar minimaal geremd 
wanneer de behandeling in een later stadium gestart werd Deze resultaten duiden aan 
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dat MMP-remmers behalve het remmen van uitzaaiing wellicht ook nuttig kunnen 
zijn om tumorgroei te remmen 
Hoofdstuk 7 bevat een overzicht van de rol die cytokinen en adhesiemoleculen 
spelen bij uitzaaiing en bij uitgroei van metastasen 
Concluderend toont het onderzoek vervat in dit proefschrift aan dat zowel exogeen 
en door de tumor geproduceerd IL-1 de hechting van melanoomcellen aan EC in vitro 
verhoogt Tevens neemt de vorming van metastasen in het door ons gebruikte 
melanoom tumorsysteem toe, hetgeen geremd kan worden door toediening van 
recombinant humaan IL-lra De oorzaak van de verhoogde hechting van 
melanoomcellen aan EC,en de verhoogde mate van metastasevorming, is IL-1 dat een 
toegenomen expressie van adhesiemoleculen, zoals ICAM-1, VCAM-1 en E-selectine, 
teweeg brengt De hechting van melanoomcellen aan EC vindt plaats via de VLA-
4/VCAM-l binding, die een kritieke rol bij de vorming van metastasen speelt De 
hechting van melanoomcellen aan EC in vitro, en de verhoogde metastasenvorming 
werden geblokeerd door de behandeling van melanoomcellen met monoclonale 
antilichamen tegen VLA-4 Ook bleek dat melanoomcellen ICAM-1 uitscheiden als zij 
met cytokinen behandeld werden, waardoor deze waarschijnlijk te weinig cel-
gebonden ICAM-1 overhouden om effectief door cytotoxische lymfocyten herkend te 
worden De functionele rol van cel-gebonden en niet cel-gebonden ICAM-1 bij 
uitzaaiing is nog niet duidelijk Een van de verdere stappen bij metastasering, de 
migratie van tumorcellen door EC en ECM, werd onderzocht Wij bestudeerden het 
effect van een synthetische remmer van MMPs, batimastat, om deze stappen te 
blokkeren Onze resultaten tonen aan dat batimastat inderdaad tumorgroei en 
uitzaaiing remt 
Nader onderzoek over de precíese rol van adhesiemoleculen en MMPs bij de 
metastasermg van melanoomcellen is nodig, teneinde nieuwe strategieën te 
ontwikkelen om tumorgroei en metastasevorming tegen te gaan 
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Riassunto 
Riassunto 
Questa tesi si propone di studiare il ruolo di citochine, di molecole adesive e di 
metalloproteinasi della matrice (MMP) nella progressione e nella metastatizzazione 
del melanoma 
L' interazione delle cellule tumorali con Γ endotelio vascolare (CE) é un passo 
importante nella formazione di metastasi In questo fenomeno sono coinvolte le 
molecole di adesione presenti su entrambi ι tipi cellulari (CE e melanoma), la cui 
espressione può essere modulata da citochine infiammatone come interleuchina-1 (IL-
1) e dal fattore di necrosi tumorale (TNF) Durante il processo metastatico le cellule 
tumorali arrestatesi nei vasi capillari, devono migrare attraverso le CE e la matrice 
extracellulare (MEC) per poi impiantarsi negli organi secondari 
Lo scopo del nostro studio e quello di chiarire alcuni aspetti di questi complessi 
meccanismi e di sviluppare terapie sperimentali volte ad inibire l'adesione della 
cellula tumorale alle CE, e la degradazione di MEC, bloccando cosi la formazione di 
metastasi 
Nel Capitolo 1 viene presentata un' introduzione e una visione della letteratura, 
con particolare attenzione al ruolo delle citochine nell' interazione cellula tumorale-
CE, e al ruolo delle MMP e dei loro inibitori nella formazione di metastasi 
Nel Capitolo 2 descriviamo che l'aumento di metastasi artificiali al polmone del 
melanoma umano A375M in topi nudi trattati con IL-1 può essere bloccata dall' 
antagonista recettonale per IL-1 (IL-lra) IL-lra inibisce significamente l'effetto di IL-1 se 
viene inoculato insieme fino a 3 ore prima del IL-1 In vitro abbiamo trovato che 
l'aumento di adesione di cellule di A375M melanoma sulle CE, attivate con IL-1, può 
essere bloccato con IL-lra Infatti IL-lra inibisce l'aumentata espressione e/o induzione 
di ICAM-1, VCAM-1 ed E-seletma su CE attivato II trattamento con lipopolisacchande 
(LPS), noto induttore di IL-1, aumenta la formazione di metastasi da A375M nei 
polmoni di topi nudi L'inoculo di IL-lra insieme о 1 ora dopo la somministrazione di 
LPS inibisce l'aumentata formazione di metastasi, suggerendo pertanto un ruolo di IL-
1 prodotto dall' ospite nella formazione di metastasi 
Lo studio presentato nel Capitolo 3 indica il coinvolgimento dell' integrina α4(Π 
(VLA-4) nella aumentata formazione di metastasi del melanoma umano A375M nei 
polmoni di topi nudi indotta da IL-1 Cellule di A375M esprimono alti livelli di VLA-4 
e aderiscono preferenzialmente su superfici stratificate con VCAM-1, il ligando per 
VLA-4 su CE Questa adesione viene inibita se le cellule di A375M sono trattate con 
anticorpi contro VLA-4 Topi trattati con IL-1 prima dell' inoculo con Λ375Μ 
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mostravano un' aumentata formazione di metastasi nel polmone II pretrattamento 
delle cellule di A375M con anticorpi contro VLA-4 bloccava completamente l 'aumento 
formazione di colonie nel polmone indotta da IL-1 Usando due cloni di melanoma 
metastatici (2/4e 2/60), che esprimono livelli differenti di VLA-4, abbiamo mostrato 
che soltanto il clone che esprime VLA-4 aderisce su superfici stratificate con VCAM-1, 
e soltanto queste cellule formano un maggior numero di colonie nel polmone di topi 
trattati con IL-1 che poteva essere inibito se le cellule venivano pretrattate con 
l'anticorpo contro VLA-4 Questi risultati dimostrano il ruolo funzionale di VLA-4 su 
cellule di melanoma nell' aumentata formazione di colonie tumorali indotte da IL-1 
Questo é probabilmente causa della interazione delle cellule tumorali con VCAM-1 
sovraespresso sulle CE attivate 
Dopo che abbiamo visto che gli anticorpi contro VLA-4 su cellule di melanoma e il 
trattamento di topi nudi con IL-lra potevano inibire l'aumentata formazione di 
metastasi nei polmoni di topi trattati con IL-1, abbiamo esaminato, nel Capitolo 4. se 
l'espressione costitutiva di IL-1 influenzava l'adesività di cellule di melanoma 
trasformate II melanoma umano A375Pé stato trasfettato con un gene che codifica per 
IL-1 Sono state isolate due colonie, la colonia-3 che non esprime e non rilascia IL-1, e 
la colonia-6 che esprime e rilascia IL-1 Entrambe le colonie sono identiche per 
l'adesione alle CE a riposo II pretrattamento delle CE con medium condizionato (MC) 
della colonia-6, ma non della colonia-3, ne aumenta l'adesione per le cellule tumorali, 
questo aumento с bloccato dell'IL-lra II trattamento delle CE con il MC della colonin-6 
ne induce l'espressione di ICAM-1, VCAM-1 e E-seletina che e bloccata da IL-lra II 
trattamento delle CE con anticorpi monoclonah contro VCAM-1 e E-seletina inibisce 
l'adesione delle cellule di melanoma A375Pe del carcinoma del colon HT-29 In vivo, 
l'inoculo ι ν di cellule della colonia-6 in topi nudi aumenta l'espressione di VCAM-1 
sull' endotelio vascolare del polmone L'arresto delle cellule di A375P radiomarcate nel 
polmone é aumentato nei topi nudi pretrattati con cellule della colonia-6, ma non 
della colonia-3 Questi risultati mostrano che IL-1 prodotta da cellule di Α375Γ e 
funzionale induce molecole adesive sulle CE che diventano più adesive per cellule 
tumorali e ne aumentano l'arresto nel polmone del topo nudo 
E' noto che il siero di pazienti con melanoma contiene alti livelli di ICAM-1 
solubile Nel Capitolo 5 abbiamo studiato l'espressione di ICAM-1 sulla superficie 
cellulare, e il rilascio di ICAM-1 solubile nel modello del melanoma umano A375M, e 
come espressione e rilascio erano regolati da citochine infiammatone Cellule non 
stimolate esprimono ICAM-1 sulla loro superficie, ma non rilasciano livelli 
significativi di ICAM-1 solubile II trattamento di cellule di A375M con IL-l,IL-6, TNF, 
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о interferone-γ (IFN-γ) aumentava l'espressione di ICAM-1 sulla superficie delle 
cellule, IL-1, TNF, e IFN-γ causavano il rilascio di ICAM-1 solubile Livelli significativi 
di ICAM-1 umano sono stati misurati nel siero di topi nudi portatori di tumori di 
A375M sottocute I livelli di ICAM-1 nel siero mostrano una correlazione positiva con 
il carico tumorale Con l'utilizzo di anticorpi monoclonah che selettivamente 
riconoscono ICAM-1 umana nel saggio di ELISA abbiano confermato l'origine umana 
di ICAM-1 nel siero del topo, e quindi dimostrato che il tumore e la fonte di ICAM-1 
solubile II rilascio di ICAM-1 dal melanoma, in risposta a citochine prodotte dall' 
ospite, può essere rilevante per il riconoscimento del tumore da parte del sistema 
immunitario Indipendentamentc da quale sia il ruolo funzionale dell' espressione e 
rilascio di ICAM-1 nella progressione tumorale, la presenza di ICAM-1 nel siero 
rappresenta un indice di prognosi del melanoma maligno 
Nel Capitolo 6 abbiamo studiato un trattamento per prevenire la degradazione di 
MEC e l'invasione del tessuto circostante da parte delle cellule tumorali Abbiamo 
saggiatola capacita anti-tumorale e anti-metastatica di batimastat, un inibitore sintetico 
delle MMP, nel melanoma murino B16-BL6 trapiantato in topi singenici La 
somministrazione intraperitoneale del batimastat inibiva la formazione di metastasi 
artificiali nel polmone inseguito all' inoculo ι ν dalle cellule di B16-BL6 L'effetto del 
batimastat e stato saggiato anche sulla formazione di metastasi spontanee in topi con 
tumore inoculato sottocute nella zampa posteriore In questi esperimenti il tumore 
primario, una volta raggiunte dimensioni palpabili, viene rimosso chirurgicamente, e 
il batimastat somministrato due volte al giorno per due settimane prima della 
chirurgia о dopo la chirurgia In entrambi gli esperimenti non si osserva una 
diminuzione significativa del numero delle metastasi, ma si osserva una riduzione 
del peso delle metastasi Infine abbiamo valutato la capacita del batimastat di 
influenzare la crescita del tumore primario La somministrazione giornaliera del 
batimastat, iniziata il giorno dell' inoculo del tumore, determinava una ritardata 
crescita del tumore primario, se il trattamento iniziava a crescita avanzata, l'inibizione 
della crescita del tumore risultava marginale I nostri dati indicano quindi che un 
inibitore delle MMP oltre ad essere attivo quale farmaco antimetastatico potrebbe 
assumere un ruolo fondamentale anche nel contenere la crescita del tumore primario 
Il Capitolo 7 e un riassunto del ruolo delle citochine e delle molecole adesive nella 
diffusione e nella formazione di metastasi Questo capitolo può essere considerato la 
discussione generale 
Concludendo, ι nostri risultati mostrano che IL-1 esogena e IL-1 prodotta dal 
tumore causano l'aumento di adesione del melanoma alle CE ¡ri vitro, la diffusione 
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del tumore, e l 'aumento di metastasi, questi fenomeni sono specificamente 
antagonizzati da IL-lra IL-1 ,indurendo l'espressione di molecole adesive sulle CE 
quali ICAM-1, VCAM-1 e E-seletina, aumenta l'adesione delle cellule di melanoma 
alle CE e la formazione di metastasi In particolare l'adesione del melanoma alle CE 
attivate e mediato dal legame VLA-4/VCAM-1 che sembra giocare un ruolo 
fondamentale nella formazione di metastasi II pretrattamento delle cellule di 
melanoma con anticorpi contro VLA-4 blocca l'adesione delle cellule tumorali alle CE 
attivate m vitro e la formazione di metastasi al polmone di topi inoculati con IL-1 Un' 
altra molecola adesiva, ICAM-1 e rilasciata in forma solubile da cellule di melanoma 
dopo trattamento con citochine II ruolo funzionale di ICAM-1 legato alla cellula о 
ICAM-1 solubile nella progressione tumorale ed in particolare nel riconoscimento da 
parte dell' ospite non e ancora chiaro 
Ter bloccare uno degli eventi successivi nella progressione metastatica, quale la 
migrazione di cellule tumorali attraverso CE e СЕМ, abbiamo studiato l'attività del 
batimastat, un inibitore sintetico delle MMP I nostri risultati indicano che batimastat 
può inibire la crescita del tumore e la formazione di metastasi 
Un'ulteriore approfondimento dei meccanismi molecolari coinvolti nel processo 
metastatico saranno indispensabili per sviluppare nuove terapie in grado di inibire la 
crescita tumorale e la formazione di metastasi 
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